Tetrahydro-imidazo [4, 5-c] pyridine derivatives as PD-L1 immunomodulators
The inhibition of PD-1/PD-L1 interaction by tetrahydro-imidazo[4,5-c]pyridine derivative compounds has solved the problem of immune response inhibition in the prior art and improved the therapeutic effect on cancer and infection.
Patent Information
- Application Number
- CN202410736059.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-06-21
- Filing Date
- 2019-05-10
- Publication Date
- 2024-11-08
AI Technical Summary
Existing therapeutic methods are difficult to effectively block the interaction between PD-1/PD-L1 proteins, leading to inhibition of immune response and affecting the therapeutic effect on cancer and infection.
A tetrahydro-imidazo[4,5-c]pyridine derivative compound is provided for inhibiting PD-1/PD-L1 interactions and enhancing or stimulating immune responses.
By inhibiting PD-1/PD-L1 interaction and enhancing the immune response, a new treatment method for cancer and infection is provided, improving the therapeutic effect.
Smart Images

Figure CN118908978A_ABST
Abstract
Description
[0001] This invention application is a divisional application based on an invention patent application with an application date of May 10, 2019, application number 201980044320.8 (international application number PCT / US2019 / 031728), and titled “Tetrahydro-imidazo[4,5-c]pyridine derivatives as PD-L1 immunomodulators”.
[0002] Heterocyclic compounds as immunomodulators
[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 670,249, filed May 11, 2018; and U.S. Provisional Application No. 62 / 688,164, filed June 21, 2018, each of which is incorporated herein by reference in its entirety. Technical Field
[0004] The present application relates to pharmaceutically active compounds. The present disclosure provides compounds and compositions and methods of use thereof. The compounds modulate PD-1 / PD-L1 protein / protein interactions and can be used to treat various diseases, including infectious diseases and cancer. Background Art
[0005] The immune system plays an important role in controlling and eradicating diseases such as cancer. However, cancer cells often develop strategies to avoid or suppress the immune system to facilitate their growth. One such mechanism is to change the expression of co-stimulatory and co-inhibitory molecules expressed on immune cells (Postow et al., J.Clinical Oncology 2015, 1-9). Blocking the signaling of immune checkpoints (such as PD-1) has been shown to be a promising and effective treatment model.
[0006] Programmed cell death-1 (PD-1), also known as CD279, is a cell surface receptor expressed on activated T cells, natural killer T cells, B cells, and macrophages (Greenwald et al., Annu. Rev. Immunol 2005, 23: 515-548; Okazaki and Honjo, Trends Immunol 2006, (4): 195-201). It acts as an intrinsic negative feedback system to prevent T cell activation, which in turn reduces autoimmunity and promotes autotolerance. In addition, PD-1 is also known to play a key role in the inhibition of antigen-specific T cell responses in diseases such as cancer and viral infections (Sharpe et al., Nat Immunol 20078, 239-245; Postow et al., J. Clinical Oncol 2015, 1-9).
[0007] The structure of PD-1 consists of an extracellular immunoglobulin variable-like domain followed by a transmembrane region and an intracellular domain (Parry et al., Mol Cell Biol 2005, 9543-9553). The intracellular domain contains two phosphorylation sites located in the immunoreceptor tyrosine-based inhibitory motif and the immunoreceptor tyrosine-based conversion motif, which indicates that PD-1 negatively regulates T cell receptor-mediated signals. PD-1 has two ligands, PD-L1 and PD-L2 (Parry et al., Mol Cell Biol 2005, 9543-9553; Latchman et al., Nat Immunol 2001, 2, 261-268), and they differ in their expression patterns. PD-L1 protein is upregulated in response to lipopolysaccharide and GM-CSF treatment on macrophages and dendritic cells, and upregulated after T cell receptor and B cell receptor signaling on T cells and B cells. PD-L1 is also highly expressed on almost all tumor cells, and expression is further increased after IFN-γ treatment (Iwai et al., PNAS 2002, 99(19):12293-7; Blank et al., Cancer Res 2004, 64(3):1140-5). In fact, tumor PD-L1 expression status has been shown to be prognostic in a variety of tumor types (Wang et al., Eur J Surg Oncol 2015; Huang et al., Oncol Rep 2015; Sabatier et al., Oncotarget 2015, 6(7):5449-5464). In contrast, PD-L2 expression is more restricted and is mainly expressed by dendritic cells (Nakae et al., J Immunol 2006, 177:566-73). The binding of PD-1 to its ligands PD-L1 and PD-L2 on T cells transmits a signal that inhibits IL-2 and IFN-γ production and cell proliferation induced after T cell receptor activation (Carter et al., Eur J Immunol 2002, 32(3):634-43; Freeman et al., J Exp Med 2000, 192(7):1027-34). The mechanism involves the recruitment of SHP-2 or SHP-1 phosphatases to inhibit T cell receptor signaling, such as Syk and Lck phosphorylation (Sharpe et al., Nat Immunol 2007, 8, 239-245).Activation of the PD-1 signaling axis also attenuates PKC-θ activation loop phosphorylation, which is required for activation of the NF-κB and AP1 pathways and production of cytokines such as IL-2, IFN-γ, and TNF (Sharpe et al., Nat Immunol 2007, 8, 239-245; Carter et al., Eur J Immunol 2002, 32(3):634-43; Freeman et al., J Exp Med 2000, 192(7):1027-34).
[0008] Several lines of evidence from preclinical animal studies indicate that PD-1 and its ligands negatively regulate immune responses. It has been demonstrated that PD-1-deficient mice develop lupus-like glomerulonephritis and dilated cardiomyopathy (Nishimura et al., Immunity 1999, 11: 141-151; Nishimura et al., Science 2001, 291: 319-322). Using the LCMV model of chronic infection, it has been demonstrated that PD-1 / PD-L1 interactions inhibit the activation, expansion, and acquisition of effector functions of virus-specific CD8 T cells (Barber et al., Nature 2006, 439, 682-7). In summary, these data support the development of therapeutic methods for blocking PD-1-mediated inhibitory signaling cascades to enhance or "rescue" T cell responses. Therefore, there is a need for new compounds that block PD-1 / PD-L1 protein / protein interactions. Summary of the invention
[0009] The present disclosure provides, inter alia, a compound of formula (I):
[0010]
[0011] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the composition variables are specified herein. The present disclosure also provides a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt or stereoisomer thereof and one or more pharmaceutically acceptable excipients or carriers.
[0012] The present disclosure also provides a method of inhibiting PD-1 / PD-L1 interaction, the method comprising administering to a patient a compound disclosed herein or a pharmaceutically acceptable salt or stereoisomer thereof.
[0013] The present disclosure also provides a method for treating a disease or condition related to the inhibition of PD-1 / PD-L1 interaction, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt or stereoisomer thereof.
[0014] The present disclosure also provides a method of enhancing, stimulating and / or increasing an immune response in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a pharmaceutically acceptable salt or stereoisomer thereof. DETAILED DESCRIPTION
[0015] I. Compounds
[0016] The present disclosure provides, inter alia, compounds of formula I:
[0017]
[0018] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0019] R 1 is methyl, CN, F, Cl or Br;
[0020] R 2 is methyl, CN, F, Cl or Br; and
[0021] R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl, C 6-10 Aryl-C 1-2 alkyl, 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C 1-2 alkyl, 4-membered to 6-membered heterocycloalkyl or 4-membered to 6-membered heterocycloalkyl-C 1-2 alkyl-, wherein 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C 1-2 alkyl, 4-membered to 6-membered heterocycloalkyl, and 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl-groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl, C 6-10 Aryl-C 1-2 alkyl, 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C 1-2 alkyl, 4-membered to 6-membered heterocycloalkyl, and 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl- groups are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of CONH2, SO2NH2, COOH, OH, CON(CH3)2, CH3, F, Cl, Br, CN, ethyl, and propyl.
[0022] In some embodiments, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0023] R 1 is methyl, CN, F, Cl or Br;
[0024] R 2 is methyl, CN, F, Cl or Br; and
[0025] R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl, C 6-10 Aryl-C 1-2 alkyl, 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C 1-2 alkyl, 4-membered to 6-membered heterocycloalkyl or 4-membered to 6-membered heterocycloalkyl-C 1-2 alkyl-, wherein 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C 1-2 alkyl, 4-membered to 6-membered heterocycloalkyl, and 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl-groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl, C 6-10 Aryl-C 1-2 alkyl, 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C 1-2 alkyl, 4-membered to 6-membered heterocycloalkyl, and 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl- groups are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of CONH2, SO2NH2, COOH, OH, CON(CH3)2, and CH3.
[0026] In some embodiments, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0027] R 1 is methyl, CN, F, Cl or Br;
[0028] R 2 is methyl, CN, F, Cl or Br; and
[0029] R3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl, C 6-10 Aryl-C 1-2 alkyl, 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C 1-2 alkyl, 4-membered to 6-membered heterocycloalkyl or 4-membered to 6-membered heterocycloalkyl-C 1-2 alkyl-, wherein 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C 1-2 alkyl, 4-membered to 6-membered heterocycloalkyl, and 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl-groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl, C 6-10 Aryl-C 1-2 alkyl, 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C 1-2 alkyl, 4-membered to 6-membered heterocycloalkyl, and 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl- groups are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of CONH2, SO2NH2, COOH and OH.
[0030] In some embodiments, R 1 is methyl, F, Cl or Br. In some embodiments, R 1 In some embodiments, R 1 is F, Cl or Br. In some embodiments, R 1 In some embodiments, R 1 is methyl or Cl. In some embodiments, R 1 In some embodiments, R 1 is F. In some embodiments, R 1 For Br.
[0031] In some embodiments, R 2 In some embodiments, R 2 In some embodiments, R 2 is F, Cl or Br. In some embodiments, R 2 In some embodiments, R 2is methyl, CN or Cl. In some embodiments, R 2 is F. In some embodiments, R 2 For Br.
[0032] In some embodiments, R 1 Cl and R 2 For Cl.
[0033] In some embodiments, R 1 Cl and R 2 It is methyl.
[0034] In some embodiments, R 1 is methyl and R 2 For Cl.
[0035] In some embodiments, R 1 Cl and R 2 For CN.
[0036] In some embodiments, R 1 is methyl and R 2 It is methyl.
[0037] In some embodiments, R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or 4- to 6-membered heterocycloalkyl, wherein the 5- to 6-membered heteroaryl-C 1-2 The alkyl and 4- to 6-membered heterocycloalkyl groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 The alkyl and 4- to 6-membered heterocycloalkyl groups are each optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2, COOH, OH, CON(CH3)2, CH3, F, Cl, Br, CN, ethyl and propyl.
[0038] In some embodiments, R 3 H, C 1-4 Alkyl, C 3-8Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or 4- to 6-membered heterocycloalkyl, wherein the 5- to 6-membered heteroaryl-C 1-2 The alkyl and 4- to 6-membered heterocycloalkyl groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 The alkyl and 4- to 6-membered heterocycloalkyl groups are each optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2, COOH, OH, CON(CH3)2, and CH3.
[0039] In some embodiments, R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or 4- to 6-membered heterocycloalkyl, wherein the 5- to 6-membered heteroaryl-C 1-2 The alkyl and 4- to 6-membered heterocycloalkyl groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group are each optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2, COOH and OH.
[0040] In some embodiments, R 3 1 or 2 substituents on are independently selected from CONH2, SO2NH2, COOH, OH, CON(CH3)2 and CH3. In some embodiments, R 3 The substituent on is CONH2. In some embodiments, R3 The substituent on is SO2NH2. In some embodiments, R 3 The substituent on is COOH. In some embodiments, R 3 In some embodiments, R 3 The substituent on is CON(CH3)2. In some embodiments, R 3 The substituent on is CH3. In some embodiments, R 3 The substituent on is F. In some embodiments, R 3 The substituent on is Cl. In some embodiments, R 3 The substituent on is Br. In some embodiments, R 3 In some embodiments, R 3 In some embodiments, R 3 The substituent is propyl.
[0041] In some embodiments, R 3 For H.
[0042] In some embodiments, R 3 C 1-4 Alkyl, optionally substituted with 1 or 2 substituents independently selected from COOH, OH and CON(CH3)2.
[0043] In some embodiments, R 3 C 1-4 Alkyl, optionally substituted with 1 or 2 substituents independently selected from COOH and OH.
[0044] In some embodiments, R 3 It is methyl, ethyl, isopropyl, 1,3-dihydroxypropan-2-yl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 3-carboxypropyl, 2-carboxy-2-methylpropyl or 4-carboxybutyl.
[0045] In some embodiments, R 3 It is methyl, ethyl, isopropyl, 1,3-dihydroxypropan-2-yl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 3-carboxypropyl or 2-carboxy-2-methylpropyl.
[0046] In some embodiments, R 3 C 3-8 Cycloalkyl, optionally substituted with 1 or 2 substituents independently selected from COOH, OH and CH3.
[0047] In some embodiments, R3 C 3-8 Cycloalkyl, optionally substituted with 1 or 2 substituents independently selected from COOH and OH.
[0048] In some embodiments, R 3 C 3-8 Cycloalkyl-C 1-2 Alkyl-, optionally substituted with 1 or 2 substituents independently selected from COOH and OH.
[0049] In some embodiments, R 3 C 6-10 Aryl-C 1-2 Alkyl, optionally substituted with 1 or 2 substituents independently selected from COOH and OH.
[0050] In some embodiments, R 3 The cyclobutyl group is cyclobutyl, 4-hydroxycyclohexyl, (1-carboxycyclopropyl)methyl, (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl, (4-carboxybicyclo[2.2.1]hept-1-yl)methyl, (4-carboxybicyclo[2.2.2]oct-1-yl)methyl, (3-carboxybicyclo[1.1.1]pent-1-yl)methyl, 4-carboxyphenethyl, (4-carboxycyclohexyl)ethyl (e.g. (trans-4-carboxycyclohexyl)ethyl or (cis-4-carboxycyclohexyl)ethyl)) or 4-carboxy-4-methylcyclohexyl (e.g. cis-4-carboxy-4-methylcyclohexyl or trans-4-carboxy-4-methylcyclohexyl).
[0051] In some embodiments, R 3 It is cyclobutyl, 4-hydroxycyclohexyl, (1-carboxycyclopropyl)methyl, (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl, (4-carboxybicyclo[2.2.1]hept-1-yl)methyl, (4-carboxybicyclo[2.2.2]oct-1-yl)methyl, (3-carboxybicyclo[1.1.1]pent-1-yl)methyl or 4-carboxyphenethyl.
[0052] In some embodiments, R 3 is a 5- to 6-membered heteroaryl-C 1-2 Alkyl, optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2 and COOH.
[0053] In some embodiments, R 3 is a 4- to 6-membered heterocycloalkyl group, optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2 and COOH.
[0054] In some embodiments, R 3It is (1H-pyrazol-3-yl)methyl, tetrahydro-2H-pyran-4-yl, 1-carbamoylpiperidin-4-yl, 1-sulfamoylpiperidin-4-yl or (3-carboxy-1H-pyrazol-5-yl)methyl.
[0055] In some embodiments, R 3 is H, methyl, ethyl, isopropyl, 1,3-dihydroxypropan-2-yl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 3-carboxypropyl, 2-carboxy-2-methylpropyl, cyclobutyl, 4-hydroxycyclohexyl, (1-carboxycyclopropyl)methyl, (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl, (4-carboxybicyclo[2.2.1]hept-1-yl)methyl, (4-carboxybicyclo[2.2.2]oct-1-yl)methyl, (3-carboxybicyclo[1.1.1 ]pentan-1-yl)methyl, 4-carboxyphenethyl, (1H-pyrazol-3-yl)methyl, tetrahydro-2H-pyran-4-yl, 1-carbamoylpiperidin-4-yl, 1-sulfamoylpiperidin-4-yl, (3-carboxy-1H-pyrazol-5-yl)methyl, 4-carboxybutyl, (4-carboxycyclohexyl)ethyl (e.g., (trans-4-carboxycyclohexyl)ethyl or (cis-4-carboxycyclohexyl)ethyl)) or 4-carboxy-4-methylcyclohexyl (e.g., cis-4-carboxy-4-methylcyclohexyl or trans-4-carboxy-4-methylcyclohexyl).
[0056] In some embodiments, R 3 is H, methyl, ethyl, isopropyl, 1,3-dihydroxypropan-2-yl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 3-carboxypropyl, 2-carboxy-2-methylpropyl, cyclobutyl, 4-hydroxycyclohexyl, (1-carboxycyclopropyl)methyl, (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl, (4-carboxybicyclo[2.2 .1]hept-1-yl)methyl, (4-carboxybicyclo[2.2.2]oct-1-yl)methyl, (3-carboxybicyclo[1.1.1]pentan-1-yl)methyl, 4-carboxyphenethyl, (1H-pyrazol-3-yl)methyl, tetrahydro-2H-pyran-4-yl, 1-carbamoylpiperidin-4-yl, 1-sulfamoylpiperidin-4-yl or (3-carboxy-1H-pyrazol-5-yl)methyl.
[0057] In some embodiments, R 3 It is methyl.
[0058] In some embodiments, R 3 It is ethyl.
[0059] In some embodiments, R 3 It is isopropyl.
[0060] In some embodiments, R 3 It is 1,3-dihydroxypropan-2-yl.
[0061] In some embodiments, R 3 It is 2,3-dihydroxypropyl.
[0062] In some embodiments, R 3 It is 2-hydroxypropyl.
[0063] In some embodiments, R 3 It is 2-hydroxyethyl.
[0064] In some embodiments, R 3 It is 3-hydroxypropyl.
[0065] In some embodiments, R 3 It is carboxymethyl.
[0066] In some embodiments, R 3 It is 3-carboxypropyl.
[0067] In some embodiments, R 3 It is 2-carboxy-2-methylpropyl.
[0068] In some embodiments, R 3 It is cyclobutyl.
[0069] In some embodiments, R 3 It is 4-hydroxycyclohexyl.
[0070] In some embodiments, R 3 It is (1-carboxycyclopropyl)methyl.
[0071] In some embodiments, R 3 It is (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl.
[0072] In some embodiments, R 3 It is (4-carboxybicyclo[2.2.1]hept-1-yl)methyl.
[0073] In some embodiments, R 3 It is (4-carboxybicyclo[2.2.2]oct-1-yl)methyl.
[0074] In some embodiments, R 3 It is (3-carboxybicyclo[1.1.1]pentan-1-yl)methyl.
[0075] In some embodiments, R 3 It is 4-carboxyphenethyl.
[0076] In some embodiments, R 3 It is (1H-pyrazol-3-yl)methyl.
[0077] In some embodiments, R 3 It is tetrahydro-2H-pyran-4-yl.
[0078] In some embodiments, R 3 It is 1-carbamoylpiperidin-4-yl.
[0079] In some embodiments, R 3 It is 1-sulfamoylpiperidin-4-yl.
[0080] In some embodiments, R 3 It is (3-carboxy-1H-pyrazol-5-yl)methyl.
[0081] In some embodiments, R 3 It is 4-carboxybutyl.
[0082] In some embodiments, R 3 is (4-carboxycyclohexyl)ethyl (e.g. (trans-4-carboxycyclohexyl)ethyl or (cis-4-carboxycyclohexyl)ethyl)).
[0083] In some embodiments, R 3 It is 4-carboxy-4-methylcyclohexyl (e.g., cis-4-carboxy-4-methylcyclohexyl or trans-4-carboxy-4-methylcyclohexyl).
[0084] In some embodiments, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0085] R 1 is methyl, CN, F, Cl or Br;
[0086] R 2 is methyl, CN, F, Cl or Br; and
[0087] R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or 4- to 6-membered heterocycloalkyl, wherein the 5- to 6-membered heteroaryl-C 1-2 The alkyl and 4- to 6-membered heterocycloalkyl groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 C1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 The alkyl and 4- to 6-membered heterocycloalkyl groups are each optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2, COOH, OH, CON(CH3)2, and CH3.
[0088] In some embodiments, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0089] R 1 is methyl, CN, F, Cl or Br;
[0090] R 2 is methyl, CN, F, Cl or Br; and
[0091] R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or 4- to 6-membered heterocycloalkyl, wherein the 5- to 6-membered heteroaryl-C 1-2 The alkyl and 4- to 6-membered heterocycloalkyl groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group are each optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2, COOH and OH.
[0092] In some embodiments, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0093] R 1 Methyl or Cl;
[0094] R 2 is methyl, CN or Cl; and
[0095] R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or 4- to 6-membered heterocycloalkyl, wherein the 5- to 6-membered heteroaryl-C 1-2 The alkyl and 4- to 6-membered heterocycloalkyl groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 The alkyl and 4- to 6-membered heterocycloalkyl groups are each optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2, COOH, OH, CON(CH3)2, and CH3.
[0096] In some embodiments, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0097] R 1 Methyl or Cl;
[0098] R 2 is methyl, CN or Cl; and
[0099] R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or 4- to 6-membered heterocycloalkyl, wherein the 5- to 6-membered heteroaryl-C 1-2 The alkyl and 4- to 6-membered heterocycloalkyl groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2Alkyl, 5- to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group are each optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2, COOH and OH.
[0100] In some embodiments, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0101] R 1 Methyl or Cl;
[0102] R 2 is methyl, CN or Cl; and
[0103] R 3 is H, methyl, ethyl, isopropyl, 1,3-dihydroxypropan-2-yl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 3-carboxypropyl, 2-carboxy-2-methylpropyl, cyclobutyl, 4-hydroxycyclohexyl, (1-carboxycyclopropyl)methyl, (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl, (4-carboxybicyclo[2.2.1]hept-1-yl)methyl, (4-carboxybicyclo[2.2.2]oct-1-yl)methyl, (3-carboxybicyclo[1.1.1 ]pentan-1-yl)methyl, 4-carboxyphenethyl, (1H-pyrazol-3-yl)methyl, tetrahydro-2H-pyran-4-yl, 1-carbamoylpiperidin-4-yl, 1-sulfamoylpiperidin-4-yl, (3-carboxy-1H-pyrazol-5-yl)methyl, 4-carboxybutyl, (4-carboxycyclohexyl)ethyl (e.g., (trans-4-carboxycyclohexyl)ethyl or (cis-4-carboxycyclohexyl)ethyl)) or 4-carboxy-4-methylcyclohexyl (e.g., cis-4-carboxy-4-methylcyclohexyl or trans-4-carboxy-4-methylcyclohexyl).
[0104] In some embodiments, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0105] R 1 Methyl or Cl;
[0106] R 2 is methyl, CN or Cl; and
[0107] R 3is H, methyl, ethyl, isopropyl, 1,3-dihydroxypropan-2-yl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 3-carboxypropyl, 2-carboxy-2-methylpropyl, cyclobutyl, 4-hydroxycyclohexyl, (1-carboxycyclopropyl)methyl, (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl, (4-carboxybicyclo[2.2 .1]hept-1-yl)methyl, (4-carboxybicyclo[2.2.2]oct-1-yl)methyl, (3-carboxybicyclo[1.1.1]pentan-1-yl)methyl, 4-carboxyphenethyl, (1H-pyrazol-3-yl)methyl, tetrahydro-2H-pyran-4-yl, 1-carbamoylpiperidin-4-yl, 1-sulfamoylpiperidin-4-yl or (3-carboxy-1H-pyrazol-5-yl)methyl.
[0108] In some embodiments, provided herein is a compound selected from the following:
[0109] 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0110] 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0111] 4-(2-(2-((2,2'-dichloro-3'-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0112] 4-(2-(2-((2,2'-dichloro-3'-(5-ethyl-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0113] 4-(2-(2-((2,2'-dichloro-3'-(5-isopropyl-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0114] 4-(2-(2-((2,2'-dichloro-3'-(5-cyclobutyl-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0115] 4-(2-(2-((3'-(5-(1-carbamoylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0116] 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-5-(1-sulfamoylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0117] 4-(2-(2-((3'-(5-((1H-pyrazol-3-yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0118] 4-(2-(2-((2,2'-dichloro-3'-(5-(1,3-dihydroxypropan-2-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0119] 4-(2-(2-((2,2'-dichloro-3'-(5-(2,3-dihydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0120] 4-(2-(2-((2,2'-dichloro-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0121] 4-(2-(2-((2,2'-dichloro-3'-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0122] 4-(2-(2-((2,2'-dichloro-3'-(5-(3-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0123] 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid);
[0124] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0125] 4-(2-(2-((3'-(5-(carboxymethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0126] 4-(2-(2-((3'-(5-(3-carboxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0127] 4-(2-(2-((3'-(5-(2-carboxy-2-methylpropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0128] 4-(2-(2-((3'-(5-((1-carboxycyclopropyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0129] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.2]octane-1-carboxylic acid;
[0130] 3-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid;
[0131] 4-(2-(2-((3'-(5-(4-carboxyphenethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0132] 5-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)-1H-pyrazole-3-carboxylic acid;
[0133] 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0134] 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0135] 4-(2-(2-((2-chloro-3'-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0136] 4-(2-(2-((3'-(5-(1-carbamoylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chloro-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0137] 4-(2-(2-((2-chloro-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0138] 4-(2-(2-((2-chloro-3'-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0139] 4,4'-(((((2-chloro-2'-methyl-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid);
[0140] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-chloro-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0141] 4-(2-(2-((3'-(5-(4-carboxyphenethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chloro-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0142] 4-(2-(2-((2'-chloro-2-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0143] 4-(2-(2-((2'-chloro-2-methyl-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0144] 4-(2-(2-((2'-chloro-3'-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0145] 4-(2-(2-((3'-(5-(1-carbamoylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-chloro-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0146] 4-(2-(2-((2'-chloro-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0147] 4-(2-(2-((2'-chloro-3'-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0148] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chloro-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0149] 4-(2-(2-((3'-(5-(4-carboxyphenethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-chloro-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0150] 4-(2-(2-((2-chloro-2'-cyano-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0151] 4-(2-(2-((2-chloro-2'-cyano-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0152] 4-(2-(2-((2-chloro-2'-cyano-3'-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0153] 4-(2-(2-((2-chloro-2'-cyano-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0154] 4-(2-(2-((2-chloro-2'-cyano-3'-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0155] 4,4'-(((((2-chloro-2'-cyano-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid);
[0156] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-chloro-2-cyano-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0157] 4-(2-(2-((2,2'-dimethyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0158] 4,4'-(((((2,2'-dimethyl-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid);
[0159] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0160] 4-(2-(2-((2,2'-dimethyl-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0161] 4-(2-(2-((3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0162] 4-(2-(2-((3'-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0163] 4-(2-(2-((2,2'-dichloro-3'-(5-(4-hydroxycyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; and
[0164] 4-(2-(2-((2-chloro-3'-(5-(4-hydroxycyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0165] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0166] In some embodiments, provided herein is a compound selected from the following:
[0167] 4-(2-(2-((3'-(5-(2-(4-carboxycyclohexyl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0168] 4-(2-(2-((3'-(5-(4-carboxybutyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0169] 4-(2-(2-((2,2'-dichloro-3'-(5-(5-(dimethylamino)-5-oxopentyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0170] 4-(2-(2-((3'-(5-(4-carboxy-4-methylcyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0171] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0172] In some embodiments, provided herein is a compound of Formula I, wherein one or more hydrogen atoms are replaced by deuterium, or a pharmaceutically acceptable salt or stereoisomer thereof.
[0173] In some embodiments, the compound is selected from the examples provided herein.
[0174] It will be further appreciated that certain features described herein for clarity in the context of separate embodiments may also be provided in combination in a single embodiment (where the embodiments are intended to be combined, as if written in a multi-subordinate form). Conversely, individual features described herein for simplicity in the context of a single embodiment may also be provided individually or in any suitable sub-combination. Thus, it is contemplated that features described as embodiments of compounds of formula (I) may be combined in any suitable combination.
[0175] At various places in this specification, certain features of compounds are disclosed in groups or in ranges. Such disclosure is specifically intended to include every individual subcombination of the members of such groups and ranges. For example, the term "C 1-6 "Alkyl" is specifically intended to individually disclose, but not be limited to, methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl.
[0176] The term "n-membered," where n is an integer, typically describes the number of ring-forming atoms in a moiety, where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridinyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl.
[0177] At various locations in this specification, variables defining a divalent linking group may be described. Each linking substituent is specifically intended to include both the forward and reverse forms of the linking substituent. For example, -NR(CR'R") n -Including-NR(CR'R") n -with-(CR'R") n NR-both and it is intended that each of the forms be disclosed individually. Where a structure requires a linking group, the Markush variable listed for that group is to be understood as the linking group. For example, if a structure requires a linking group and the Markush group definition for that variable lists "alkyl" or "aryl", it is to be understood that "alkyl" or "aryl" represents a linking alkylene or arylene, respectively.
[0178] The term "substituted" means that an atom or a group of atoms formally replaces hydrogen as a "substituent" connected to another group. Unless otherwise noted, the term "substituted" refers to any level of substitution, such as monosubstitution, disubstitution, trisubstitution, tetrasubstitution or pentasubstitution (where such substitution is permitted). Substituents are independently selected, and substitutions can be located at any chemically accessible position. It should be understood that substitution at a given atom is limited by valence. It should be understood that substitution at a given atom produces a chemically stable molecule. The phrase "optionally substituted" means unsubstituted or substituted. The term "substituted" means that a hydrogen atom is removed and replaced by a substituent. A single divalent substituent (such as oxo) can replace two hydrogen atoms.
[0179] The term "C n-m " indicates a range including the endpoint, where n and m are integers and indicate the number of carbons. Examples include C 1-4 , C 1-6 wait.
[0180] The term "alkyl" used alone or in combination with other terms refers to a saturated hydrocarbon group which may be a straight chain or a branched chain. n-m"Alkyl" refers to an alkyl group having n to m carbon atoms. Alkyl formally corresponds to an alkane with one CH bond replaced by the point of attachment of the alkyl group to the rest of the compound. In some embodiments, the alkyl group contains 1 to 6 carbon atoms, 1 to 4 carbon atoms, 1 to 3 carbon atoms, or 1 to 2 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl; higher homologues such as 2-methyl-1-butyl, n-pentyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl, and the like.
[0181] The term "alkenyl", used alone or in combination with other terms, refers to a straight or branched hydrocarbon radical corresponding to an alkyl radical having one or more carbon-carbon double bonds. Alkenyl formally corresponds to an alkene with one CH bond replaced by the point of attachment of the alkenyl to the rest of the compound. n-m "Alkenyl" refers to an alkenyl group having n to m carbons. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms. Exemplary alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like.
[0182] The term "alkynyl", used alone or in combination with other terms, refers to a straight or branched hydrocarbon radical corresponding to an alkyl radical having one or more carbon-carbon triple bonds. Alkynyl formally corresponds to an alkyne in which one CH bond is replaced by the point of attachment of the alkyl radical to the rest of the compound. n-m "Alkynyl" refers to an alkynyl group having n to m carbons. Exemplary alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.
[0183] The term "alkylene", used alone or in combination with other terms, refers to a divalent alkyl linking group. Alkylene formally corresponds to an alkane with two CH bonds replaced by the point of attachment of the alkylene group to the rest of the compound. n-m “Alkylene” refers to an alkylene radical having n to m carbon atoms. Examples of alkylene radicals include, but are not limited to, ethane-1,2-diyl, propylene-1,3-diyl, propylene-1,2-diyl, butane-1,4-diyl, butane-1,3-diyl, butane-1,2-diyl, 2-methyl-propylene-1,3-diyl, and the like.
[0184] The term "alkoxy", used alone or in combination with other terms, refers to a radical of the formula -O-alkyl, wherein alkyl is as defined above. n-m "Alkoxy" refers to an alkoxy group in which the alkyl group has n to m carbons. Exemplary alkoxy groups include methoxy, ethoxy, propoxy (eg, n-propoxy and isopropoxy), tert-butoxy, and the like. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0185] The term "amino" refers to a group of formula -NH2.
[0186] The term "carbamoyl" refers to a group of formula -C(O)NH2.
[0187] The term "carbonyl," employed alone or in combination with other terms, refers to a -C(=O)- group, which may also be written as C(O).
[0188] The term "cyano" or "nitrile" refers to a radical of the formula -C≡N, which may also be written as -CN.
[0189] The term "halo" or "halogen" used alone or in combination with other terms refers to fluoro, chloro, bromo and iodo. In some embodiments, "halo" refers to a halogen atom selected from F, Cl or Br. In some embodiments, halo is F. In some embodiments, halo is Cl.
[0190] As used herein, the term "haloalkyl" refers to an alkyl group in which one or more of the hydrogen atoms have been replaced by a halogen atom. n-m "Haloalkyl" refers to a C group having n to m carbon atoms and at least one to {2 (n to m) + 1} halogen atoms (these halogen atoms may be the same or different). n-m In some embodiments, the halogen atom is a fluorine atom. In some embodiments, the haloalkyl group has 1 to 6 or 1 to 4 carbon atoms. Exemplary haloalkyl groups include CF3, C2F5, CHF2, CCl3, CHCl2, C2Cl5, etc. In some embodiments, the haloalkyl group is a fluoroalkyl group.
[0191] The term "haloalkoxy" used alone or in combination with other terms refers to a group having the formula -O-haloalkyl, wherein haloalkyl is as defined above. n-m "Haloalkoxy" refers to a haloalkoxy group whose haloalkyl group has n to m carbons. Exemplary haloalkoxy groups include trifluoromethoxy and the like. In some embodiments, the haloalkoxy group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.
[0192] The term "oxo" refers to an oxygen atom as a divalent substituent, which forms a carbonyl when attached to carbon, or forms a sulfoxide or sulfone group when attached to a heteroatom, or an N-oxide group. In some embodiments, the heterocyclyl group may be optionally substituted with 1 or 2 oxo (=O) substituents.
[0193] The term "sulfido" refers to a sulfur atom as a divalent substituent which when attached to carbon forms a thiocarbonyl (C=S).
[0194] The term "aromatic" refers to a carbocyclic or heterocyclic ring having one or more polyunsaturated rings containing aromatic character (ie, having (4n+2) delocalized π (pi) electrons, where n is an integer).
[0195] The term "aryl", used alone or in combination with other terms, refers to an aromatic hydrocarbon group which may be monocyclic or polycyclic (eg, having two fused rings). n-m "Aryl" refers to an aromatic radical having n to m ring carbon atoms. Aryl radicals include, for example, phenyl, naphthyl, dihydroindenyl, indenyl, and the like. In some embodiments, an aryl radical has 6 to about 10 carbon atoms. In some embodiments, an aryl radical has 6 carbon atoms. In some embodiments, an aryl radical has 10 carbon atoms. In some embodiments, an aryl radical is phenyl. In some embodiments, an aryl radical is naphthyl.
[0196] As used herein, the term "heteroatom" is intended to include boron, phosphorus, sulfur, oxygen, and nitrogen.
[0197] The term "heteroaryl" or "heteroaromatic" used alone or in combination with other terms refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from sulfur, oxygen and nitrogen. In some embodiments, the heteroaryl ring has 1, 2, 3 or 4 heteroatom ring members independently selected from boron, phosphorus, nitrogen, sulfur and oxygen. In some embodiments, any ring-forming N in the heteroaryl moiety can be an N-oxide. In some embodiments, the heteroaryl has 5-14 ring atoms, including carbon atoms and 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-14 or 5-10 ring atoms, including carbon atoms and 1, 2, 3 or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl has 5-6 ring atoms and 1 or 2 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, the heteroaryl is a five-membered or six-membered heteroaryl ring. In other embodiments, heteroaryl is an eight-, nine- or ten-membered fused bicyclic heteroaryl ring. Exemplary heteroaryl includes, but is not limited to, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, azolyl, oxazolyl, thiazolyl, imidazolyl, furanyl, thiophenyl, quinolyl, isoquinolyl, naphthyridinyl (including 1,2-naphthyridine, 1,3-naphthyridine, 1,4-naphthyridine, 1,5-naphthyridine, 1,6-naphthyridine, 1,7-naphthyridine, 1,8-naphthyridine, 2,3-naphthyridine and 2,6-naphthyridine), indolyl, benzophenylthio, benzofuranyl, benzisoxazolyl, imidazo[1,2-b]thiazolyl, purinyl, etc.
[0198] A five-membered heteroaryl ring is a heteroaryl group having five ring atoms, wherein one or more (e.g., 1, 2, or 3) of the ring atoms are independently selected from N, O, and S. Exemplary five-membered heteroaryl ring groups include thienyl, furanyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl.
[0199] A six-membered heteroaryl ring is a heteroaryl group having six ring atoms, wherein one or more (eg 1, 2 or 3) of the ring atoms are independently selected from N, O and S. Exemplary six-membered ring heteroaryl groups are pyridinyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
[0200] The term "cycloalkyl" used alone or in combination with other terms refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic or polycyclic) including cyclized alkyl and alkenyl groups. n-m "Cycloalkyl" refers to a cycloalkyl group having n to m ring member carbon atoms. Cycloalkyl groups may include monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) groups and spirocyclic groups. Cycloalkyl groups may have 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring carbon atoms (C 3-14 In some embodiments, the cycloalkyl group has 3 to 14 ring members, 3 to 10 ring members, 3 to 6 ring members, 3 to 5 ring members, or 3 to 4 ring members. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. In some embodiments, the cycloalkyl group is C 3-6Monocyclic cycloalkyl. The ring-forming carbon atoms of the cycloalkyl group may be optionally oxidized to form oxo or sulfide groups. Cycloalkyl also includes cycloalkylene. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. The definition of cycloalkyl also includes a portion having one or more aromatic rings fused to the cycloalkyl ring (i.e., having a bond in common with the cycloalkyl ring), such as benzo or thienyl derivatives of cyclopentane, cyclohexane, etc. The cycloalkyl group containing the fused aromatic ring can be connected by any ring-forming atom, including the ring-forming atom of the fused aromatic ring. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, bicyclo[1.1.1]pentanyl, bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, etc. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0201] The term "heterocycloalkyl", used alone or in combination with other terms, refers to a non-aromatic ring or ring system, which may optionally contain one or more alkenylene groups as part of the ring structure, which has at least one heteroatom ring member independently selected from boron, nitrogen, sulfur, oxygen and phosphorus, and which has 4-14 ring members, 4-10 ring members, 4-7 ring members or 4-6 ring members. The term "heterocycloalkyl" includes monocyclic 4-membered, 5-membered, 6-membered and 7-membered heterocycloalkyls. Heterocycloalkyls may include monocyclic or bicyclic or polycyclic (e.g., having two or three fused or bridged rings) ring systems or spirocycles. In some embodiments, heterocycloalkyls are monocyclic groups having 1, 2 or 3 heteroatoms independently selected from nitrogen, sulfur and oxygen. The ring-forming carbon atoms and heteroatoms of the heterocycloalkyl group may be optionally oxidized to form oxo or sulfide groups or other oxidative linkages (e.g., C(O), S(O), C(S) or S(O)2, N-oxides, etc.) or the nitrogen atom may be quaternized. The heterocycloalkyl group may be connected by ring-forming carbon atoms or ring-forming heteroatoms. In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 double bonds. The definition of heterocycloalkyl also includes a portion having one or more aromatic rings fused to the heterocycloalkyl ring (i.e., having a bond in common with the heterocycloalkyl ring), such as benzo or thienyl derivatives such as piperidine, morpholine, azobenzene, etc. The heterocycloalkyl group containing a fused aromatic ring may be connected by any ring-forming atom, including the ring-forming atom of the fused aromatic ring. Examples of heterocycloalkyl groups include azetidinyl, azepanyl, dihydrobenzofuranyl, dihydrofuranyl, dihydropyranyl, morpholinyl, 3-oxa-9-azaspiro[5.5]undecanoyl, 1-oxa-8-azaspiro[4.5]decyl, piperidinyl, piperazinyl, oxopiperazinyl, pyranyl, pyrrolidinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydroquinolinyl, tropanyl, 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridinyl, and thiomorpholinyl.
[0202] In certain positions, the definition or embodiment refers to a specific ring (e.g., azetidine ring, pyridine ring, etc.). Unless otherwise indicated, these rings may be connected to any ring member, provided that the valence of the atom is not exceeded. For example, the azetidine ring may be connected to any position of the ring, while the azetidine-3-yl ring is connected to the 3-position.
[0203] The compounds described herein may be asymmetric (e.g., have one or more stereocenters). Unless otherwise indicated, all stereoisomers, such as enantiomers and diastereomers, are intended. Compounds of the present invention containing asymmetrically substituted carbon atoms can be separated into optically active or racemic forms. Methods for preparing optically active forms from non-optically active starting materials are known in the art, such as by resolving racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, etc. may also be present in the compounds described herein, and all such stable isomers are encompassed in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and can be separated into mixtures of isomers or separated isomeric forms.
[0204] The racemic mixture of compound can be split by any one of many methods known in the art. One method includes the fractional recrystallization using chiral splitting acid, which is an optically active salified organic acid. The splitting agent suitable for the fractional recrystallization method is, for example, an optically active acid, such as tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or various optically active camphorsulfonic acids, such as β-camphorsulfonic acid, in the form of D and L. Other splitting agents suitable for the fractional crystallization method include α-methyl-benzyl-amine (such as S and R forms, or diastereoisomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, etc.
[0205] Resolution of the racemic mixture can also be performed by elution on a column packed with an optically active resolving agent (eg, dinitrobenzoylphenylglycine). Suitable elution solvent compositions can be determined by one skilled in the art.
[0206] In some embodiments, the compounds of the invention have an (R)-configuration. In other embodiments, the compounds have an (S)-configuration. Unless otherwise indicated, in compounds with more than one chiral center, each of the chiral centers in the compound may independently be (R) or (S).
[0207] The compounds of the present invention also include tautomeric forms. Tautomeric forms are produced by the exchange of single bonds with adjacent double bonds and the accompanying proton migration. Tautomeric forms include prototropic tautomers, which are isomeric protonation states with the same empirical formula and total charge. Exemplary prototropic tautomers include keto-enol pairs, amide-imidic acid pairs, lactam-lactim pairs, enamine-imine pairs, and cyclic forms, wherein protons can occupy two or more positions of heterocyclic systems, such as 1H-imidazoles and 3H-imidazoles, 1H-1,2,4-triazoles, 2H-1,2,4-triazoles and 4H-1,2,4-triazoles, 1H-isoindoles and 2H-isoindoles and 1H-pyrazoles and 2H-pyrazoles. Tautomeric forms can be in equilibrium or locked into a form in space by appropriate substitution.
[0208] The compounds of the present invention may also include all isotopes of atoms present in the intermediate or final compound. Isotopes include those atoms with the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. One or more constituent atoms of the compounds of the present invention may be replaced or substituted with isotopes of atoms in natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom. For example, one or more hydrogen atoms in the compounds of the present disclosure may be replaced or substituted with deuterium. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 deuterium atoms. The synthetic method for incorporating isotopes into organic compounds is known in the art.
[0209] As used herein, the term "compound" is intended to include all stereoisomers, geometric isomers, tautomers and isotopes of the displayed structure. The term is also intended to refer to compounds of the present invention, no matter how they are prepared, such as synthetically, by biological processes (such as metabolic or enzymatic conversion) or a combination thereof.
[0210] All compounds and pharmaceutically acceptable salts thereof may exist with other substances (such as water and solvents) (e.g., hydrates and solvates) or may be isolated. When in the solid state, the compounds described herein and their salts may exist in various forms and may, for example, take the form of solvates, including hydrates. The compound may be in any solid state form, such as a polymorph or solvate, so unless explicitly stated, reference to the compound and its salt in this specification should be understood to encompass any solid state form of the compound.
[0211] In some embodiments, the compounds of the invention or their salts are substantially isolated. "Substantially isolated" means that the compound is at least partially or substantially separated from the environment in which it is formed or detected. Partial separation can include, for example, a composition enriched in the compounds of the invention. Substantially isolated can include a composition containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% of the compounds of the invention or their salts by weight.
[0212] The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit / risk ratio.
[0213] The expressions "ambient temperature" and "room temperature" as used herein are understood in the art and generally refer to a temperature approximately the temperature of the room in which the reaction is carried out, such as reaction temperature, for example a temperature of about 20°C to about 30°C.
[0214] The present invention also includes pharmaceutically acceptable salts of the compounds described herein. The term "pharmaceutically acceptable salt" refers to a derivative of a disclosed compound in which the parent compound is modified by converting an existing acid or base moiety into its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral acid or organic acid salts of basic residues such as amines; alkali metal or organic salts of acidic residues such as carboxylic acids; etc. Pharmaceutically acceptable salts of the present invention include non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. Pharmaceutically acceptable salts of the present invention can be synthesized from parent compounds containing basic or acidic moieties by conventional chemical methods. In general, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of an appropriate base or acid in water or an organic solvent or a mixture of the two; in general, non-aqueous media such as ether, ethyl acetate, alcohols (e.g., methanol, ethanol, isopropanol or butanol) or acetonitrile (MeCN) are preferred. Lists of suitable salts can be found in Remington's Pharmaceutical Sciences, 17th edition, (Mack Publishing Company, Easton, 1985), page 1418; Berge et al., J. Pharm. Sci., 1977, 66 (1), 1-19 and Stahl et al., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (Wiley, 2002). In some embodiments, the compounds described herein include N-oxide forms.
[0215] II. Synthesis
[0216] The compounds of the present invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of a number of possible synthetic routes.
[0217] The reactions for preparing the compounds of the invention can be carried out in suitable solvents that can be easily selected by those skilled in the art of organic synthesis. Suitable solvents can be substantially non-reactive with starting materials (reactants), intermediates or products at the temperature at which the reaction is carried out (e.g., a temperature that can range from the solvent freezing temperature to the solvent boiling temperature). A given reaction can be carried out in one solvent or in a mixture of more than one solvent. Depending on the particular reaction step, a solvent suitable for use in a particular reaction step can be selected by a skilled artisan.
[0218] The preparation of the compounds of the invention may involve the protection and deprotection of various chemical groups. The need for protection and deprotection and the selection of appropriate protecting groups can be readily determined by those skilled in the art. For example, Kocienski, Protecting Groups, (Thieme, 2007); Robertson, Protecting Group Chemistry, (Oxford University Press, 2000); Smith et al., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 6th edition (Wiley, 2007); Peturssion et al., "Protecting Groups in Carbohydrate Chemistry", J. Chem. Educ., 1997, 74 (11), 1297; and Wuts et al., Protective Groups in Organic Synthesis, 4th edition, (Wiley, 2006) describe the chemical properties of protecting groups.
[0219] The reaction can be monitored by any suitable method known in the art. For example, the reaction can be monitored by spectroscopic means such as nuclear magnetic resonance spectroscopy (e.g. 1 H or 13 C), infrared spectroscopy, spectrophotometry (eg, UV-visible), mass spectrometry), or by chromatography, such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
[0220] Compounds of Formula 1-8 can be synthesized using the method shown in Scheme 1. Boc-protected compound 1-1 can be deprotected under acidic conditions (e.g., hydrochloric acid or trifluoroacetic acid) to provide amine 1-2. Palladium-catalyzed cross-coupling reaction of halo-substituted compound 1-2 with boronate ester of Formula 1-3 under standard conditions (such as Suzuki coupling reaction, for example, in the presence of a palladium catalyst and a suitable base) can produce compounds of Formula 1-4. Reaction of amine 1-4 with methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate 1-5 under reductive amination conditions (e.g., sodium triacetoxyborohydride or sodium cyanoborohydride as a reducing agent) produces compounds of Formula 1-6. After removal of the Boc group of compound 1-6 under acidic conditions (e.g., hydrochloric acid or trifluoroacetic acid), R can be converted to 1-6 by reductive amination using the corresponding aldehyde or ketone. 3 The group is introduced to the resulting amine to produce a compound of Formula 1-7. The ester 1-7 can then be hydrolyzed under basic conditions to provide the desired compound of Formula 1-8.
[0221] Process 1
[0222]
[0223] Compounds of Formula 2-4 can be synthesized using the method shown in Scheme 2. The free amine in compound 2-1 can be protected with Boc. The resulting compound can be deprotonated by a strong base such as, but not limited to, n-butyl lithium to produce the corresponding heteroaryl lithium intermediate, which can be further reacted with an alkyl chloroformate to give an ester of Formula 2-2. The reaction of ester 2-2 with a halo-substituted aniline 2-3 in the presence of a suitable base such as, but not limited to, potassium tert-butoxide can give the desired compound of Formula 2-4.
[0224] Process 2
[0225]
[0226] Compounds of formula 3-2 can be prepared according to Scheme 3. Halo-substituted compounds 3-1 can be converted to boronate esters 3-2 under standard conditions [e.g., in the presence of bis(pinacolato)diboron and a palladium catalyst such as tetrakis(triphenylphosphine)palladium(0) and palladium(II) acetate].
[0227] Process 3
[0228]
[0229] Compound 4-4 can be prepared according to Scheme 4. Alcohol 4-1 can be converted to aldehyde 4-2 in the presence of an oxidizing agent such as, but not limited to, Dess-Martin periodinane or pyridinium chlorochromate. Aldehyde 4-2 can be extended by one carbon atom in the presence of (methoxymethyl)triphenylphosphonium chloride 4-3 in a Wittig reaction to form an enol ether, which can be further hydrolyzed under acidic conditions (e.g., hydrochloric acid) to provide the desired compound 4-4.
[0230] Process 4
[0231]
[0232] III. Uses of the Compounds
[0233] The compounds of the present disclosure can inhibit the activity of PD-1 / PD-L1 protein / protein interactions, and therefore, are suitable for treating diseases and conditions associated with the activity of PD-1 and diseases and conditions associated with PD-L1, including its interaction with other proteins (such as PD-1 and B7-1 (CD80)). In certain embodiments, the compounds of the present disclosure or their pharmaceutically acceptable salts or stereoisomers can be used for therapeutic administration to enhance, stimulate and / or increase immunity in cancer, chronic infection or sepsis, including enhancing the response to vaccination. In some embodiments, the present disclosure provides a method of inhibiting PD-1 / PD-L1 protein / protein interactions. The method comprises administering to an individual or patient a compound of formula (I) or any one of the structural formulas described herein or a compound or its pharmaceutically acceptable salt or stereoisomer as described in any one of the claims and described herein. The compounds of the present disclosure can be used alone, in combination with other agents or therapies, or as an adjuvant or a new adjuvant for the treatment of diseases or conditions, including cancer or infectious diseases. For the uses described herein, any of the compounds of the present disclosure, including any one of its embodiments, can be used.
[0234] The compounds disclosed herein inhibit PD-1 / PD-L1 protein / protein interactions, resulting in PD-1 pathway blockade. Blockade of PD-1 can enhance the immune response of mammals, including humans, to cancer cells and infectious diseases. In some embodiments, the present disclosure uses a compound of formula (I) or a salt or stereoisomer thereof in vivo to inhibit the growth of cancerous tumors and provide treatment for individuals or patients. A compound of formula (I) or any one of the structural formulas described herein or a compound or salt or stereoisomer thereof as described in any one of the claims and described herein can be used to inhibit the growth of cancerous tumors. Alternatively, as described below, a compound of formula (I) or any one of the structural formulas described herein or a compound or salt or stereoisomer thereof as described in any one of the claims and described herein can be used in combination with other agents or standard cancer treatments. In one embodiment, the present disclosure provides a method for inhibiting tumor cell growth in vitro. The method comprises contacting tumor cells in vitro with a compound of formula (I) or any one of the structural formulas described herein or a compound or salt or stereoisomer thereof as described in any one of the claims and described herein. In another embodiment, the present disclosure provides a method of inhibiting tumor cell growth in an individual or patient. The method comprises administering to an individual or patient in need thereof a therapeutically effective amount of a compound of formula (I) or any of the structural formulas described herein, or a compound as recited in any one of the claims and described herein, or a salt or stereoisomer thereof.
[0235] In some embodiments, provided herein is a method for treating cancer. The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or any of the structural formulas described herein, a compound as recited in any one of the claims and described herein, or a salt thereof. Examples of cancers include those cancers whose growth can be inhibited using the disclosed compounds and cancers that are typically responsive to immunotherapy.
[0236] In some embodiments, the present disclosure provides a method of enhancing, stimulating and / or increasing an immune response in a patient. The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or any of the structural formulas described herein, a compound or composition as recited in any one of the claims and described herein, or a salt thereof.
[0237] Examples of cancers that can be treated using the compounds of the present disclosure include, but are not limited to, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's Disease, non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, chronic or acute leukemia (including acute myeloid leukemia), chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, bladder cancer, kidney or urethra cancer, renal pelvis cancer, central nervous system (CNS) neoplasms, primary CNS lymphomas, tumor angiogenesis, spinal cord tumors (spinal cord tumors), spinal cord tumors, ... axis tumor), brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers (including those induced by asbestos), and combinations of said cancers. The disclosed compounds can also be used to treat metastatic cancers, especially metastatic cancers expressing PD-L1.
[0238] In some embodiments, cancers treatable using the disclosed compounds include melanoma (e.g., metastatic malignant melanoma, cutaneous melanoma), renal cancer (e.g., clear cell carcinoma), prostate cancer (e.g., hormone-refractory prostate adenocarcinoma), breast cancer (e.g., invasive breast cancer), colon cancer, lung cancer (e.g., non-small cell lung cancer and small cell lung cancer), squamous cell head and neck cancer (e.g., squamous cell carcinoma of the head and neck), urothelial cancer (e.g., bladder cancer, non-muscle invasive bladder cancer (NMIBC)), and high microsatellite instability (MSI) 高 ) cancer. In addition, the present disclosure includes refractory or recurrent malignancies whose growth can be inhibited using the disclosed compounds.
[0239] In some embodiments, cancers treatable using the compounds of the present disclosure include, but are not limited to, solid tumors (e.g., prostate cancer, colon cancer, esophageal cancer, endometrial cancer, ovarian cancer, uterine cancer, kidney cancer, liver cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, head and neck cancer, thyroid cancer, glioblastoma, sarcoma, bladder cancer, etc.), blood cancers (e.g., lymphoma, leukemia (such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML)), DLBCL, mantle cell lymphoma, non-Hodgkin lymphoma (including relapsed or refractory NHL and relapsed follicular lymphoma), Hodgkin lymphoma, or multiple myeloma), and combinations of the aforementioned cancers.
[0240] In some embodiments, cancers treatable using the compounds of the present disclosure include, but are not limited to, bile duct carcinoma, cholangiocarcinoma, biliary tract cancer, triple negative breast cancer, rhabdomyosarcoma, small cell lung cancer, leiomyosarcoma, hepatocellular carcinoma, Ewing's sarcoma, brain cancer, brain tumor, astrocytoma, neuroblastoma, neurofibroma, basal cell carcinoma, chondrosarcoma, epithelioid sarcoma, eye cancer, fallopian tube cancer, gastrointestinal cancer, gastrointestinal stromal tumor, hairy cell leukemia, intestinal cancer, islet cell carcinoma, oral cancer, mouth cancer, pharyngeal cancer, laryngeal cancer, lip cancer, mesothelioma, neck cancer, nasal cancer, eye cancer, ocular melanoma, pelvic cancer, rectal cancer, renal cell carcinoma, salivary gland cancer, sinus cancer, spinal cord cancer, tongue cancer, tubular carcinoma, urethral cancer, and ureteral cancer.
[0241] In some embodiments, the compounds of the present disclosure are useful for treating sickle cell disease and sickle cell anemia.
[0242] In some embodiments, diseases and indications treatable using the compounds of the present invention include, but are not limited to, hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, cancers of the nervous system, gynecological cancers, and skin cancers.
[0243] Exemplary blood cancers include lymphomas and leukemias, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, non-Hodgkin lymphoma (including relapsed or refractory NHL and relapsed follicular lymphoma), Hodgkin lymphoma, myeloproliferative disorders (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), and essential thrombocythemia (ET)), myelodysplastic syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), and multiple myeloma (MM).
[0244] Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, hamartoma, and teratoma.
[0245] Exemplary lung cancers include non-small cell lung cancer (NSCLC) (e.g., squamous cell NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell carcinoma, undifferentiated small cell carcinoma, undifferentiated large cell carcinoma, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, enchondromatous hamartoma, and mesothelioma.
[0246] Exemplary gastrointestinal cancers include esophageal cancer (carcinoma, squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), gastric cancer (carcinoma, lymphoma, leiomyosarcoma, adenocarcinoma), pancreatic cancer (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small intestine cancer (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), colorectal cancer (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), and colorectal cancer (e.g., colorectal adenocarcinoma).
[0247] Exemplary genitourinary tract cancers include renal cancer (adenocarcinoma, Wilm's tumor [nephroblastoma]), bladder and urethral cancer (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate cancer (adenocarcinoma, sarcoma), and testicular cancer (seminoma, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatous tumor, lipoma). In some embodiments, the cancer is a urological cancer (e.g., papillary renal carcinoma, testicular germ cell carcinoma, refractory renal cell carcinoma, clear cell renal carcinoma, or prostate adenocarcinoma).
[0248] Exemplary liver cancers include hepatoma (liver cell carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.
[0249] Exemplary bone cancers include, e.g., osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondroma (osteocartilaginous exostosis), benign enchondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumor.
[0250] Exemplary nervous system cancers include cancers of the skull (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), meningeal cancers (meningiomas, meningosarcomas, gliomatosis), brain cancers (astrocytomas, meduoblastomas, gliomas, ependymomas, germinal histoma (pinealoma), glioblastomas, glioblastoma multiforme, oligodendritic gliomas, schwannomas, retinoblastomas, congenital tumors), and spinal cord cancers (neurofibromas, meningiomas, gliomas, sarcomas), as well as neuroblastoma and Lhermitte-Duclos disease.
[0251] Exemplary gynecological cancers include uterine cancer (endometrial cancer), cervical cancer (cervical carcinoma, preneoplastic cervical dysplasia), ovarian cancer (ovarian carcinoma (serous cystadenocarcinoma, serous adenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granular theca cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulvar cancer (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vaginal cancer (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tube cancer (carcinoma).
[0252] Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma (e.g., cutaneous squamous cell carcinoma), Kaposi's sarcoma, dysplastic nevus, lipoma, hemangioma, dermatofibroma, and keloid. In some embodiments, diseases and indications treatable using the compounds of the present disclosure include, but are not limited to, sickle cell disease (e.g., sickle cell anemia), triple negative breast cancer (TNBC), myelodysplastic syndrome, testicular cancer, bile duct cancer, esophageal cancer, and urothelial cancer.
[0253] PD-1 pathway blocking using the disclosed compounds can also be used to treat infections, such as viral, bacterial, fungal and parasitic infections. The present disclosure provides a method for treating infections such as viral infections. The method comprises administering to a patient in need a therapeutically effective amount of a compound of any one of the formula (I) or the structural formula described herein, a compound as described in any one of the claims and described herein, and a salt thereof. Examples of viruses causing infections treatable by the disclosed methods include, but are not limited to, human immunodeficiency virus, human papilloma virus, influenza, hepatitis A, B, C or D virus, adenovirus, poxvirus, herpes simplex virus, human cytomegalovirus, severe acute respiratory syndrome virus, Ebola virus and measles virus. In some embodiments, viruses that cause infections treatable by the disclosed methods include, but are not limited to, hepatitis (type A, B, or C), herpes viruses (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, flavivirus, echovirus, rhinovirus, coxsackie virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papilloma virus, molluscum virus, polio virus, rabies virus, JC virus, tuberculosis, and arboviral encephalitis virus.
[0254] The present disclosure provides a method for treating bacterial infection. The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of any one of formula (I) or structural formulae as described herein, a compound as described in any one of claims and described herein, or a salt thereof. Non-limiting examples of pathogenic bacteria causing infections treatable by the methods of the present disclosure include chlamydia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, legionella, diphtheria, salmonella, bacillus, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria.
[0255] The present disclosure provides a method for treating fungal infections. The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or any one of the structural formulas described herein, a compound as described in any one of the claims and described herein, or a salt thereof. Non-limiting examples of pathogenic bacteria causing infections treatable by the methods of the present disclosure include Candida (albicans, krusei, glabrata, tropical, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Mucorales (Mucor, Absidia, Rhizopus), Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis, and Histoplasma capsulatum.
[0256] The present disclosure provides a method for treating parasitic infections, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or any of the structural formulae described herein, a compound as recited in any one of the claims and described herein, or a salt thereof. Non-limiting examples of pathogenic parasites causing infections treatable by the disclosed methods include Entamoeba histolytica, E. coli, Naegleria fowleri, Acanthamoeba sp., Giardia lamblia, Cryptosporidium, Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Nippostrongylus brasiliensis.
[0257] The present disclosure provides a method for treating a neurodegenerative disease or condition. The method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or any of the structural formulas described herein, a compound as recited in any one of the claims and described herein, or a salt thereof. Non-limiting examples of neurodegenerative diseases or conditions include Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, motor neuron disease, spinocerebellar ataxia, and spinal muscular atrophy.
[0258] It is believed that the compounds of formula (I) or any of its embodiments may have a satisfactory pharmacological profile and promising biopharmaceutical properties, such as toxicological profile, metabolic and pharmacokinetic properties, solubility and permeability. It will be appreciated that the determination of appropriate biopharmaceutical properties is within the knowledge of those skilled in the art, such as determining cytotoxicity in cells or inhibiting certain targets or pathways to determine potential toxicity.
[0259] The terms "subject" or "patient" are used interchangeably to refer to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses, or primates, and most preferably humans.
[0260] The phrase "therapeutically effective amount" refers to that amount of an active compound or agent that elicits in a tissue, system, animal, individual or human the biological or medical response that is being sought by the researcher, veterinarian, medical doctor or other clinician.
[0261] As used herein, the terms "treating" or "treatment" refer to one or more of the following: (1) inhibiting a disease; e.g., inhibiting a disease, disorder or condition in a subject experiencing or exhibiting the pathology or symptoms of the disease, disorder or condition (i.e., preventing further development of the pathology and / or symptoms); and (2) ameliorating a disease; e.g., ameliorating a disease, disorder or condition in a subject experiencing or exhibiting the pathology or symptoms of the disease, disorder or condition (i.e., reversing the pathology and / or symptoms), such as reducing the severity of the disease.
[0262] In some embodiments, the compounds of the invention are useful for preventing or reducing the risk of developing any of the diseases mentioned herein; for example, preventing or reducing the risk of developing the disease, disorder or condition in an individual who may be susceptible to the disease, disorder or condition but has not yet experienced or displayed the pathology or symptoms of the disease.
[0263] Combination therapy
[0264] Immune checkpoint therapy
[0265] The compounds of the present disclosure can be combined with one or more immune checkpoint inhibitors for treating diseases, such as cancer or infection. Exemplary immune checkpoint inhibitors include inhibitors for immune checkpoint molecules such as the following: CBL-B, CD20, CD122, CD96, CD73, CD47, CSF1R, JAK, PI3Kδ, PI3Kγ, TAM, arginase, HPK1, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, TIGIT, CD112R, VISTA, PD-1, PD-L1 and PD-L2. In some embodiments, immune checkpoint molecules are selected from the following stimulatory checkpoint molecules: CD27, CD28, CD40, ICOS, OX40, GITR and CD137 (4-1BB). In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from the following: A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, TIGIT and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from the following: KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFβ inhibitors.
[0266] In some embodiments, the compounds provided herein can be used in combination with agonists of one or more immune checkpoint molecules, such as OX40, CD27, GITR, and CD137 (also known as 4-1BB).
[0267] In some embodiments, the agonist of an immune checkpoint molecule is an agonist of OX40, CD27, CD28, GITR, ICOS, CD40, TLR7 / 8, and CD137 (also known as 4-1BB).
[0268] In some embodiments, the agonist of CD137 is urelumab. In some embodiments, the agonist of CD137 is utomilumab.
[0269] In some embodiments, the agonist of the immune checkpoint molecule is an agonist of CD40. In some embodiments, the agonist of CD40 is CP-870893, ADC-1013, CDX-1140, SEA-CD40, RO7009789, JNJ-64457107, APX-005M or Chi Lob 7 / 4.
[0270] In some embodiments, the agonist of the immune checkpoint molecule is an agonist of ICOS. In some embodiments, the agonist of ICOS is GSK-3359609, JTX-2011 or MEDI-570.
[0271] In some embodiments, the agonist of the immune checkpoint molecule is an agonist of CD28. In some embodiments, the agonist of CD28 is theralizumab.
[0272] In some embodiments, the agonist of the immune checkpoint molecule is an agonist of CD27. In some embodiments, the agonist of CD27 is varlilumab.
[0273] In some embodiments, the agonist of the immune checkpoint molecule is an agonist of TLR7 / 8. In some embodiments, the agonist of TLR7 / 8 is MEDI9197.
[0274] In some embodiments, the inhibitor of an immune checkpoint molecule is an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.
[0275] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, such as an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, cemiplimab, spartalizumab, camrelizumab, cetrelimab, toripalimab, sintilimab, SHR-1210, PDR001, MGA012, PDR001, AB122, AMP-224, JTX-4014, BGB-108, BCD-100, BAT1306, LZM009, AK105, HLX10, or TSR-042. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the anti-PD1 antibody is pembrolizumab. In some embodiments, the anti-PD-1 monoclonal antibody is MGA012. In some embodiments, the anti-PD1 antibody is SHR-1210. One or more other anti-cancer agents include antibody therapeutics such as 4-1BB (e.g., usurelumab, utomimab).
[0276] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-L1, such as an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), durvalumab Atezolizumab Avelumab MSB0010718C, tislelizumab, FAZ053, KN035, CS1001, SHR-1316, CBT-502, A167, STI-A101, CK-301, BGB-A333, MSB-2311, HLX20, or LY3300054. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A or MEDI4736.
[0277] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-1 and PD-L1, such as an anti-PD-1 / PD-L1 bispecific antibody. In some embodiments, the anti-PD-1 / PD-L1 bispecific antibody is MCLA-136.
[0278] In some embodiments, the inhibitor is MCLA-145.
[0279] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CTLA-4, such as an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab, AGEN1884 or CP-675,206.
[0280] In some embodiments, the inhibitor of immune checkpoint molecules is an inhibitor of PD-1 and CTLA-4, such as an anti-PD-1 / CTLA-4 bispecific antibody. In some embodiments, the anti-PD-1 / CTLA-4 antibody is AK104.
[0281] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of LAG3, such as an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016, LAG525, INCAGN2385, or eftilagimod alpha (IMP321).
[0282] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CD73. In some embodiments, the inhibitor of CD73 is oleclumab. In some embodiments, the inhibitor of CD73 is MEDI9447.
[0283] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of TIGIT. In some embodiments, the inhibitor of TIGIT is OMP-31M32.
[0284] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of VISTA. In some embodiments, the inhibitor of VISTA is JNJ-61610588 or CA-170.
[0285] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of B7-H3. In some embodiments, the inhibitor of B7-H3 is enoblituzumab, MGD009 or 8H9.
[0286] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of KIR. In some embodiments, the inhibitor of KIR is lirilumab or IPH4102.
[0287] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of A2aR. In some embodiments, the inhibitor of A2aR is CPI-444.
[0288] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of TGF-β. In some embodiments, the inhibitor of TGF-β is trabedersen, galusertinib or M7824.
[0289] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PI3K-γ. In some embodiments, the inhibitor of PI3K-γ is IPI-549.
[0290] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CD47. In some embodiments, the inhibitor of CD47 is Hu5F9-G4 or TTI-621.
[0291] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CD70. In some embodiments, the inhibitor of CD70 is cusatuzumab or BMS-936561.
[0292] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of TIM3, such as an anti-TIM3 antibody. In some embodiments, the anti-TIM3 antibody is INCAGN2390, MBG453 or TSR-022.
[0293] In some embodiments, the agonist of the immune checkpoint molecule is an agonist of GITR, such as an anti-GITR antibody. In some embodiments, the agonist is TRX518, MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, MEDI1873 or MEDI6469.
[0294] In some embodiments, the agonist of the immune checkpoint molecule is an agonist of OX40, such as an OX40 agonist antibody or an OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562, MOXR-0916, PF-04518600, GSK3174998, BMS-986178 or 9B12. In some embodiments, the OX40L fusion protein is MEDI6383.
[0295] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CD20, such as an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is obinutuzumab or rituximab.
[0296] The compounds of the present disclosure can be used in combination with bispecific antibodies. In some embodiments, one of the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, OX40, TIM3, LAG3, CD137, ICOS, CD3 or TGFβ receptor. In some embodiments, the bispecific antibody binds to PD-1 and PD-L1. In some embodiments, the bispecific antibody that binds to PD-1 and PD-L1 is MCLA-136. In some embodiments, the bispecific antibody binds to PD-L1 and CTLA-4. In some embodiments, the bispecific antibody that binds to PD-L1 and CTLA-4 is AK104.
[0297] In some embodiments, the compounds of the present disclosure may be used in combination with one or more metabolic enzyme inhibitors. In some embodiments, the metabolic enzyme inhibitor is an inhibitor of IDO1, TDO or arginase. Examples of IDO1 inhibitors include epacadostat, NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099 and LY338196.
[0298] As provided throughout, additional compounds, inhibitors, agents, etc. can be combined with the compounds of the present invention in a single or sequential dosage form, or they can be administered simultaneously or sequentially as separate dosage forms.
[0299] II. Cancer Therapy
[0300] Cancer cell growth and survival can be affected by dysfunction of multiple biological pathways. Therefore, it may be useful to combine inhibitors of different mechanisms (such as enzyme inhibitors, signal transduction inhibitors, chromatin dynamics inhibitors, or immune response modifiers) to treat such disorders. Targeting more than one signal transduction pathway (or more than one biomolecule involved in a given signal transduction pathway) can reduce the likelihood of resistance in a cell population and / or reduce the toxicity of treatment.
[0301] The compounds of the present disclosure can be used in combination with one or more other therapies for treating diseases such as cancer or infection. Examples of diseases and indications that can be treated with combination therapy include those described herein. Examples of cancer include solid tumors and non-solid tumors, such as liquid tumors, blood cancers. Examples of infection include viral infection, bacterial infection, fungal infection or parasitic infection. For example, the compounds of the present disclosure can be combined with one or more inhibitors of the following kinases for treating cancer: Akt1, Akt2, Akt3, BCL2, CDK, TGF-βR, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IDH2, IGF-1R, IR-R, PDGFαR, PDGFβR, PI3K (α, β, γ, δ and multiple or selective), CSF1R, KIT, FLK-I I, KDR / FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, PARP, Ron, Sea, TRKA, TRKB, TRKC, TAM kinases (Axl, Mer, Tyro3), FLT3, VEGFR / Flt2, Flt4, EphA1, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. In some embodiments, the compounds of the present disclosure can be combined with one or more of the following inhibitors to treat cancer or infection. Non-limiting examples of inhibitors that can be used in combination with the compounds of the present disclosure for treating cancer and infection include FGFR inhibitors (FGFR1, FGFR2, FGFR3 or FGFR4,For example, pemigatinib (INCY54828), INCB62079), EGFR (also known as ErB-1 or HER-1) inhibitors (e.g., erlotinib, gefitinib, vandetanib, orsimertinib, cetuximab, necitumumab, or panitumumab), VEGFR inhibitors or pathway blockers (e.g., bevacizumab, pazopanib, sunitinib, ib), sorafenib, axitinib, regorafenib, ponatinib, cabozantinib, vandetanib, ramucirumab, lenvatinib, ziv-aflibercept), PARP inhibitors (e.g., olaparib, rucaparib, veliparib, or niraparib), JAK inhibitors (JAK1 and / or JAK2,For example, ruxolitinib, baricitinib or itacitinib (INCB39110), IDO inhibitors (e.g., icaridostat, NLG919 or BMS-986205, MK7162), LSD1 inhibitors (e.g., INCB59872 and INCB60003), TDO inhibitors, PI3K-δ inhibitors (e.g., Parsaclisib (INCB50465) and INCB50797), PI3K-γ inhibitors (such as P I3K-γ selective inhibitors), Pim inhibitors (e.g., INCB53914), EGFR inhibitors (also known as ErB-1 or HER-1; e.g., erlotinib, gefitinib, vandetanib, osimertinib, cetuximab, necituzumab, or panitumumab), VEGFR inhibitors or pathway blockers (e.g., bevacizumab, pazopanib, sunitinib, sorafenib, axitinib, regorafenib, ponatinib, cabozantinib, vandetanib, ramucirumab, lenvatinib, ziv-aflibercept), PARP inhibitors (e.g., olaparib, rucaparib, veliparib, talazopanib, tala zoparib or niraparib), CSF1R inhibitors, TAM receptor tyrosine kinases (Tyro-3, Axl and Mer), adenosine receptor antagonists (e.g., A2a / A2b receptor antagonists), HPK1 inhibitors, chemokine receptor inhibitors (e.g., CCR2 or CCR5 inhibitors), SHP1 / 2 phosphatase inhibitors, histone deacetylase inhibitors (HDAC) (such as HDAC8 inhibitors), angiogenesis inhibitors, interleukin receptor inhibitors, bromodomain and super terminal family member inhibitors (e.g., bromodomain inhibitors or BET inhibitors, such as INCB54329 and INCB54329), B57643), arginase inhibitors (INCB001158), PARP inhibitors (such as rucaparib or olaparib), sitravatinib, B-Raf inhibitor-MEK inhibitor combinations (such as encorafenib plus binimetinib, dabrafenib plus trametinib or cobimetinib plus vemurafenib), and adenosine receptor antagonists or combinations thereof.
[0302] In some embodiments, the compounds of the present disclosure may be combined with a TLR7 agonist (eg, imiquimod).
[0303] The compounds of the present disclosure can be further used in combination with other methods for treating cancer, such as by chemotherapy, radiotherapy, tumor targeting therapy, adjuvant therapy, immunotherapy or surgery. Examples of immunotherapy include cytokine therapy (e.g., interferon, GM-CSF, G-CSF, IL-2), CRS-207 immunotherapy, cancer vaccines, monoclonal antibodies, bispecific or multispecific antibodies, antibody drug conjugates, adoptive T cell transfer, Toll receptor agonists, STING agonists, RIG-I agonists, oncolytic virus therapy and immunomodulatory small molecules, including thalidomide or JAK1 / 2 inhibitors, PI3Kδ inhibitors, etc. The compound can be administered in combination with one or more anticancer drugs (such as chemotherapeutic agents). Examples of chemotherapeutic agents include any of the following: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, hexamethylmelamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bevacizumab, bexarotene, baricitinib, bleomycin, bortezomib, intravenous busulfan, lfan), oral busulfan, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium), dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphatephosphate), etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon α2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, folinic acid, leuprolide acetate acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase, pegfilgrastim, pemetrexeddisodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide ide), testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, and zoledronate.
[0304] One or more other anticancer agents include antibody therapeutics, such as trastuzumab (Herceptin), antibodies to costimulatory molecules (such as CTLA-4, such as ipilimumab; 4-1BB, such as relutumab, utumumab), antibodies to PD-1 and PD-L1, or antibodies to cytokines (IL-10, TGF-β, etc.). Examples of PD-1 and / or PD-L1 antibodies that can be combined with the disclosed compounds for the treatment of cancer or infection (such as viral, bacterial, fungal, and parasitic infections) include, but are not limited to, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, and SHR-1210.
[0305] The disclosed compounds may further be used in combination with one or more anti-inflammatory agents, steroids, immunosuppressants, or therapeutic antibodies.
[0306] The compound of formula (I) or any of the structural formulae as described herein, the compound as recited in any of the claims and described herein, or a salt thereof, can be combined with another immunogenic agent such as cancer cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immunostimulatory cytokines. Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens (such as gp100, MAGE antigens, Trp-2, MARTI, and / or tyrosinase peptides) or tumor cells transfected to express the cytokine GM-CSF.
[0307] Compounds of formula (I) or any of the structural formulae as described herein, compounds as described in any of the claims and described herein, or salts thereof, may be used in combination with vaccination regimens for the treatment of cancer. In some embodiments, tumor cells are transduced to express GM-CSF. In some embodiments, tumor vaccines include proteins from viruses implicated in human cancers, such as human papillomavirus (HPV), hepatitis viruses (HBV and HCV), and Kaposi's herpes sarcoma virus (KHSV). In some embodiments, compounds of the present disclosure may be used in combination with tumor-specific antigens isolated from the tumor tissue itself, such as heat shock proteins. In some embodiments, compounds of formula (I) or any of the structural formulae as described herein, compounds as described in any of the claims and described herein, or salts thereof, may be combined with dendritic cell immunization to activate an effective anti-tumor response.
[0308] The disclosed compounds can be used in combination with bispecific macrocyclic peptides that target effector cells expressing Fcα or Fcγ receptors to tumor cells. The disclosed compounds can also be combined with macrocyclic peptides that activate the host immune response.
[0309] The disclosed compounds can be used in combination with bone marrow transplantation to treat a variety of tumors of hematopoietic origin.
[0310] The compounds of formula (I) or any of the structural formulae described herein, the compounds as recited in any of the claims and described herein, or salts thereof, can be used in combination with vaccines to stimulate immune responses to pathogens, toxins, and self-antigens. Examples of pathogens for which this treatment method may be particularly useful include pathogens for which there are currently no effective vaccines or pathogens for which conventional vaccines are not fully effective. These pathogens include, but are not limited to, HIV, hepatitis (types A, B, and C), influenza, herpes, Giardia, malaria, Leishmania, Staphylococcus aureus, Pseudomonas aeruginosa.
[0311] Viruses that cause infections treatable by the disclosed methods include, but are not limited to, human papillomavirus, influenza, hepatitis A, B, C, or D, adenovirus, poxvirus, herpes simplex virus, human cytomegalovirus, severe acute respiratory syndrome virus, Ebola virus, measles virus, herpes viruses (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein-Barr virus), flavivirus, echovirus, rhinovirus, coxsackievirus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papilloma virus, molluscum virus, polio virus, rabies virus, JC virus, and arboviral encephalitis virus.
[0312] Pathogenic bacteria that cause infections treatable by the disclosed methods include, but are not limited to, Chlamydia, Rickettsia, Mycobacterium, Staphylococcus, Streptococcus, Pneumococcus, Meningococcus and Gonorrhea, Klebsiella, Proteus, Serratia, Pseudomonas, Legionella, Diphtheria, Salmonella, Bacillus, Cholera, Tetanus, Botulism, Anthrax, Plague, Leptospirosis, and Lyme's Disease bacteria.
[0313] Pathogenic bacteria causing infections treatable by the disclosed methods include Candida species (Candida albicans, Candida krusei, Candida glabrata, Candida tropicalis, etc.), Cryptococcus neoformans, Aspergillus species (Aspergillus fumigatus, Aspergillus niger, etc.), Mucorales species (Mucor, Absidia, Rhizopus), Sporothrix schenckii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis, and Histoplasma capsulatum.
[0314] Pathogenic parasites that cause infections treatable by the disclosed methods include, but are not limited to, Entamoeba histolytica, Escherichia coli, Nilenlia fowleri, Acanthamoeba, Giardia lamblia, Cryptosporidium, Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Ancylostoma brasiliensis.
[0315] When more than one agent is administered to a patient, they may be administered simultaneously, separately, sequentially, or in combination (eg, for more than two agents).
[0316] IV. Formulation, Dosage Forms, and Administration
[0317] When used as a drug, the compounds of the present disclosure can be administered in the form of a pharmaceutical composition. Therefore, the present disclosure provides a composition comprising a compound of formula (I) or any one of the structural formulas described herein, a compound as described in any one of the claims and described herein, or a pharmaceutically acceptable salt thereof, or any one of its embodiments, and at least one pharmaceutically acceptable carrier or excipient. These compositions can be prepared in a manner well known in the pharmaceutical technology and can be administered by a variety of routes, depending on whether local or systemic treatment is indicated and the area to be treated. Administration can be surface (including transdermal, transepidermal, transocular, and to mucous membranes, including intranasal, vaginal, and rectal delivery), transpulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular, or injection or infusion; or intracranial, such as intrathecal or intraventricular administration. Parenteral administration can be in the form of a single rapid dose, or can be performed, for example, by a continuous infusion pump. Pharmaceutical compositions and formulations for topical administration may include dermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers; aqueous, powder or oily bases; thickeners and the like may be necessary or desirable.
[0318] The present invention also includes pharmaceutical compositions containing a combination of a disclosed compound or a pharmaceutically acceptable salt thereof as an active ingredient and one or more pharmaceutically acceptable carriers or excipients. In some embodiments, the composition is suitable for topical administration. When preparing the composition of the present invention, the active ingredient is typically mixed with an excipient, diluted by the excipient or sealed in such a carrier in the form of, for example, a capsule, a sachet, paper or other container. When an excipient acts as a diluent, it can be a solid, semisolid or liquid material that acts as a vehicle, carrier or medium for the active ingredient. Therefore, the composition can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solids or in liquid media), ointments containing, for example, up to 10% by weight of active compounds, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
[0319] When preparing a formulation, the active compound may be ground to provide an appropriate particle size before combining with other ingredients. If the active compound is substantially insoluble, it may be ground to a particle size of less than 200 mesh. If the active compound is substantially water-soluble, the particle size may be adjusted by grinding to provide a substantially uniform distribution in the formulation, for example, about 40 mesh.
[0320] The compounds of the invention may be ground using known milling procedures such as wet milling to obtain particle sizes suitable for tablet formation and other formulation types. Finely divided (nanoparticulate) formulations of the compounds of the invention may be prepared by methods known in the art, see for example WO2002 / 000196.
[0321] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose. The formulation may additionally include: lubricants such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preservatives such as methyl-benzoate and propylhydroxy-benzoate; sweeteners; and flavoring agents. The compositions of the present invention may be formulated to provide rapid, sustained or delayed release of the active ingredient after administration to a patient using procedures known in the art.
[0322] In some embodiments, the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the silicified microcrystalline cellulose comprises about 98 w / w% microcrystalline cellulose and about 2 w / w% silicon dioxide.
[0323] In some embodiments, the composition is a sustained release composition comprising at least one compound described herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier or excipient. In some embodiments, the composition comprises at least one compound described herein or a pharmaceutically acceptable salt thereof and at least one component selected from the following: microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide. In some embodiments, the composition comprises at least one compound described herein or a pharmaceutically acceptable salt thereof and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose. In some embodiments, the composition comprises at least one compound described herein or a pharmaceutically acceptable salt thereof and microcrystalline cellulose, lactose monohydrate and polyethylene oxide. In some embodiments, the composition further comprises magnesium stearate or silicon dioxide. In some embodiments, the microcrystalline cellulose is Avicel PH102 TM In some embodiments, the lactose monohydrate is Fast-flo 316 TM In some embodiments, the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208K4M (e.g., Methocel K4 M Premier TM ) and / or hydroxypropyl methylcellulose 2208K100LV (e.g. Methocel K00LV TMIn some embodiments, the polyethylene oxide is polyethylene oxide WSR 1105 (eg, Polyox WSR 1105v).
[0324] In some embodiments, the composition is prepared using a wet granulation method. In some embodiments, the composition is prepared using a dry granulation method.
[0325] The composition can be formulated into a unit dosage form, each dose containing about 5 to about 1,000 mg (1 g), more typically about 100 mg to about 500 mg of the active ingredient. In some embodiments, each dose contains about 10 mg of the active ingredient. In some embodiments, each dose contains about 50 mg of the active ingredient. In some embodiments, each dose contains about 25 mg of the active ingredient. The term "unit dosage form" refers to a physically discrete unit suitable as a single dose for human subjects and other mammals, each unit containing a predetermined amount of active material calculated to produce the desired therapeutic effect in combination with a suitable pharmaceutical excipient.
[0326] The components used to formulate the pharmaceutical composition are of high purity and are substantially free of potentially harmful contaminants (e.g., at least national food grade, usually at least analytical grade, and more typically at least pharmaceutical grade). In particular, for human consumption, the composition is preferably manufactured or formulated under good manufacturing practice standards as specified in applicable regulations of the US Food and Drug Administration. For example, suitable formulations may be sterile and / or substantially isotonic and / or fully comply with all good manufacturing practice regulations of the US Food and Drug Administration.
[0327] The active compound can be effective over a wide dosage range and is generally administered in a therapeutically effective amount. However, it should be understood that the actual amount of compound administered will generally be determined by the physician based on the relevant circumstances, including the condition to be treated, the selected route of administration, the actual compound administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, etc.
[0328] The therapeutic dose of the compounds of the present invention may vary according to, for example, the specific use for treatment, the mode of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The ratio or concentration of the compounds of the present invention in the pharmaceutical composition may vary according to many factors, including dosage, chemical properties (e.g., hydrophobicity), and route of administration. For example, the compounds of the present invention may be provided in a physiological buffered aqueous solution containing about 0.1 to about 10% w / v of the compound for parenteral administration. Some typical dosage ranges are about 1 μg to about 1 g per kilogram of body weight per day. In some embodiments, the dosage range is about 0.01 mg to about 100 mg per kilogram of body weight per day. The dosage may depend on variables such as the type and degree of progression of the disease or condition, the overall health status of a particular patient, the relative biological efficacy of the selected compound, the formulation of the excipient, and its route of administration. The effective dose can be inferred from a dose-response curve obtained from an in vitro or animal model test system.
[0329] For the preparation of solid compositions such as tablets, the main active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of the compound of the invention. When these preformulation compositions are referred to as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be easily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing, for example, about 0.1 to about 1000 mg of the active ingredient of the invention.
[0330] The tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form that provides an advantage of prolonged action. For example, a tablet or pill may include an inner dose and an outer dose component, the latter being in the form of a film on the former. The two components may be separated by an enteric layer that resists disintegration in the stomach and allows the inner component to be delivered intact to the duodenum or delayed in release. A variety of materials may be used for such enteric layers or coatings, including many polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.
[0331] Liquid forms into which the compounds and compositions of the invention can be incorporated for oral or injection administration include aqueous solutions, appropriately flavored syrups, aqueous or oily suspensions and emulsions flavored with edible oils (such as cottonseed oil, sesame oil, coconut oil or peanut oil), as well as elixirs and similar pharmaceutical vehicles.
[0332] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, and powders. As described above, liquid or solid compositions may contain suitable pharmaceutically acceptable excipients. In some embodiments, the composition is administered by oral or nasal respiratory routes to obtain local or systemic effects. The composition may be atomized by the use of an inert gas. The atomized solution may be breathed directly from the atomizing device or the atomizing device may be connected to a mask, a tent, or an intermittent positive pressure breathing machine. Solutions, suspensions, or powder compositions may be administered orally or nasally from a device that delivers the formulation in an appropriate manner.
[0333] The topical preparation may contain one or more conventional carriers. In some embodiments, the ointment may contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white vaseline, etc. The carrier composition of the cream may be a combination of water and glycerol and one or more other components (for example, glyceryl monostearate, PEG-glyceryl monostearate and cetyl stearyl alcohol). Isopropyl alcohol and water may be used to prepare gels in combination with other components (such as glycerol, hydroxyethyl cellulose, etc.). In some embodiments, the topical preparation contains at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2 or at least about 5wt% of the compounds of the present invention. The topical preparation may be suitably packaged in, for example, a 100g tube, which may be optionally associated with instructions for treating selected indications (for example, psoriasis or other skin disorders).
[0334] The amount of the compound or composition administered to a patient will vary depending on what is being administered, the purpose of the administration (such as prevention or treatment), the patient's state, the mode of administration, etc. In therapeutic applications, the composition can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. The effective dose will depend on the disease condition being treated and will be determined by the attending clinician based on factors such as the severity of the disease, the patient's age, weight, and general condition, etc.
[0335] The composition administered to the patient may be in the form of the pharmaceutical composition described above. These compositions may be sterilized by conventional sterilization techniques, or may be aseptically filtered. The aqueous solution may be packaged for use as is, or lyophilized, and the lyophilized preparation may be combined with a sterile aqueous carrier prior to administration. The pH value of the compound formulation will typically be between 3 and 11, more preferably 5 to 9 and most preferably 7 to 8. It should be understood that the use of some of the aforementioned excipients, carriers or stabilizers will cause the formation of a pharmaceutical salt.
[0336] The therapeutic dose of the compounds of the present invention may vary according to, for example, the specific use for treatment, the mode of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The ratio or concentration of the compounds of the present invention in the pharmaceutical composition may vary according to many factors, including dosage, chemical properties (e.g., hydrophobicity), and route of administration. For example, the compounds of the present invention may be provided in a physiological buffered aqueous solution containing about 0.1 to about 10% w / v of the compound for parenteral administration. Some typical dosage ranges are about 1 μg to about 1 g per kilogram of body weight per day. In some embodiments, the dosage range is about 0.01 mg to about 100 mg per kilogram of body weight per day. The dosage may depend on variables such as the type and degree of progression of the disease or condition, the overall health status of a particular patient, the relative biological efficacy of the selected compound, the formulation of the excipient, and its route of administration. The effective dose can be inferred from a dose-response curve obtained from an in vitro or animal model test system.
[0337] V. Labeled Compounds and Analytical Methods
[0338] The disclosed compounds can also be used to study biological processes in normal and abnormal tissues. Therefore, another aspect of the present invention relates to labeled compounds of the present invention (radioactive labels, fluorescent labels, etc.), which are suitable not only for imaging techniques but also for in vitro and in vivo analysis, for localization and quantification of PD-1 or PD-L1 proteins in tissue samples (including humans), and for identifying PD-L1 ligands by inhibiting the binding of labeled compounds. Therefore, the present invention includes PD-1 / PD-L1 binding assays containing such labeled compounds.
[0339] The present invention also includes isotopically labeled compounds of the present disclosure. An "isotopically" or "radiolabeled" compound is a compound of the present disclosure in which one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated into the compounds of the present disclosure include, but are not limited to 3 H (also written as T for tritium), 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 18 F. 35 S. 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br, 123 I.124 I. 125 I and 131 I. For example, one or more hydrogen atoms in the disclosed compounds may be replaced by deuterium atoms (e.g., C 1-6 One or more hydrogen atoms of the alkyl group may be optionally replaced with a deuterium atom, such as -CD3 replacing -CH3). In some embodiments, the alkyl group in formula (I) may be perdeuterated.
[0340] One or more constituent atoms of the compounds presented herein may be replaced or substituted with isotopes of atoms of natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1-2, 1-3, 1-4, 1-5 or 1-6 deuterium atoms. In some embodiments, all hydrogen atoms in the compound may be replaced or substituted by deuterium atoms.
[0341] Synthetic methods for incorporating isotopes into organic compounds are known in the art (Deuterium Labeling in Organic Chemistry, Alan F. Thomas (New York, NY, Appleton-Century-Crofts, 1971; The Renaissance of H / D Exchange, Jens Atzrodt, Volker Derdau, Thorsten Fey and Jochen Zimmermann, Angew. Chem. Int. Ed. 2007, 7744-7765; The Organic Chemistry of Isotopic Labelling, James R. Hanson, Royal Society of Chemistry, 2011). Isotopically labeled compounds can be used in a variety of studies, such as NMR spectroscopy, metabolic experiments and / or analysis.
[0342] Substitution with heavier isotopes such as deuterium may provide certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and therefore may be preferred in some cases. (See, e.g., A. Kerekes et al. J. Med. Chem. 2011, 54, 201-210; R. Xu et al. J. Label Compd. Radiopharm. 2015, 58, 308-312). In particular, substitution at one or more metabolic sites may provide one or more of the therapeutic advantages.
[0343] The radionuclide incorporated into the radiolabeled compounds of the invention will depend on the specific application of the radiolabeled compound. For example, for in vitro PD-L1 protein labeling and competition assays, incorporating 3 H. 14 C. 82 Br, 125 I. 131 I or 35 Compounds of S will generally be the most suitable. For radiographic applications, 11 C. 18 F. 125 I. 123 I. 124 I. 131 I. 75 Br, 76 Br or 77 Br may be applicable.
[0344] It is understood that a "radiolabeled" or "labeled compound" is a compound that incorporates at least one radionuclide. In some embodiments, the radionuclide is selected from the group consisting of: 3 H. 14 C. 125 I. 35 S and 82 Br.
[0345] The present disclosure may also include synthetic methods for incorporating radioisotopes into compounds of the present disclosure.Synthetic methods for incorporating radioisotopes into organic compounds are well known in the art, and those skilled in the art will readily recognize methods applicable to the compounds of the present disclosure.
[0346] The labeled compounds of the present invention can be used in screening assays to identify and / or evaluate compounds. For example, the ability to bind to the PD-L1 protein can be assessed by monitoring the concentration change of the labeled newly synthesized or identified compound (i.e., the test compound) when in contact with the PD-L1 protein through a tracking label. For example, the ability of the test compound (labeled) to reduce the binding of another compound (i.e., the standard compound) known to bind to the PD-L1 protein can be assessed. Therefore, the ability of the test compound to compete with the standard compound for binding to the PD-L1 protein is directly related to its binding affinity. On the contrary, in other screening assays, the standard compound is labeled, and the test compound is not labeled. Therefore, the concentration of the labeled standard compound is monitored to assess the competition between the standard compound and the test compound, and thus determine the relative binding affinity of the test compound.
[0347] VI. Kit
[0348] The present disclosure also includes pharmaceutical kits useful, for example, for treating or preventing diseases or conditions associated with the activity of PD-L1 (including its interaction with other proteins such as PD-1 and B7-1 (CD80)), such as cancer or infection, comprising one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or any of its embodiments. As will be readily apparent to those skilled in the art, such kits may also include one or more of the various conventional pharmaceutical kit components, such as containers containing one or more pharmaceutically acceptable carriers, additional containers, etc. Instructions in the form of inserts or labels may also be included in the kit, indicating the amounts of the components to be administered, guidelines for administration, and / or guidelines for mixing the components.
[0349] The following abbreviations may be used herein: aq. (aqueous); br (broad); d (doublet); dd (doublet); DCM (dichloromethane); DMF (N,N-dimethylformamide); Et (ethyl); EtOAc (ethyl acetate); g (gram); h (hour); HPLC (high performance liquid chromatography); Hz (hertz); J (coupling constant); LCMS (liquid chromatography-mass spectrometry); m (multiplet); M (molar); MS (mass spectrometry); Me (methyl); MeCN (acetonitrile) ; MeOH (methanol); mg (milligram); min. (minute); mL (milliliter); mmol (millimole); nM (nanomole); NMR (nuclear magnetic resonance spectroscopy); Ph (phenyl); rt (room temperature), s (singlet); t (triplet or tertiary); TBS (tert-butyldimethylsilyl); tert (tertiary); tt (triplet); TFA (trifluoroacetic acid); THF (tetrahydrofuran); μg (microgram); μL (microliter); μM (micromolar); wt% (weight %).
[0350] The present invention will be described in more detail through specific examples. The following examples are provided for illustrative purposes and are not intended to limit the present invention in any way. One skilled in the art will readily recognize a number of non-critical parameters that can be changed or modified to obtain substantially the same results. According to at least one assay described herein, the compounds of the examples have been found to inhibit the activity of PD-1 / PD-L1 protein / protein interactions.
[0351] Example
[0352] The following provides experimental procedures for compounds of the invention. Some of the prepared compounds were subjected to open access preparative LCMS purification on a Waters mass-guided fractionation system. The basic equipment settings, protocols, and control software for operating these systems have been described in detail in the literature. See, for example, Blom, "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 2002, 4, 295-301; Blom et al., "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. Combi. Chem., 2003, 5, 670-83; and Blom et al., "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. Combi. Chem., 2004, 6, 874-883.
[0353] Example 1
[0354] 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0355]
[0356] Step 1: tert-Butyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate
[0357]
[0358] A solution of 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (Accela, catalog number SY032476: 2.0 g, 14.58 mmol) and (Boc)2O (3.38 mL, 14.58 mmol) in dichloromethane (60 mL) was stirred at room temperature for 1 h. The reaction was quenched with saturated aqueous NaHCO3 and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was used directly in the next step without further purification. C 12 H 20 LC-MS calculated for N3O2 (M+H) + : m / z = 238.2: Experimen tal value 238.2.
[0359] Step 2: 1-Methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridine-2,5(4H)-dicarboxylic acid 5-tert-butyl ester 2-methyl ester
[0360]
[0361] A solution of n-butyllithium in hexanes (2.5 M, 7.00 mL, 17.49 mmol) was added to a cold (-78 °C) solution of tert-butyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Step 1: 3.46 g, 14.58 mmol) in tetrahydrofuran (60.0 mL). The reaction mixture was stirred at -78 °C for 10 min, then methyl chloroformate (1.69 mL, 21.87 mmol) was added. After stirring at -78 °C for 30 min, the reaction was then quenched with saturated aqueous NaHCO3 and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column, eluting with 0-80% ethyl acetate / hexanes to provide the desired product. C 14 H 22 LC-MS calculated for N3O4 (M+H) + : m / z = 296.2: Experimen tal value 296.3.
[0362] Step 3: tert-Butyl 2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate
[0363]
[0364] Potassium tert-butoxide in THF (1.0 M, 3.39 mL, 3.39 mmol) was added to a solution of 5-tert-butyl 2-methyl 1-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridine-2,5(4H)-dicarboxylate (Step 2: 500 mg, 1.69 mmol) and 3-bromo-2-chloroaniline (350 mg, 1.69 mmol) in tetrahydrofuran (12.0 mL). After stirring at room temperature for 30 min, the reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0-50% ethyl acetate / hexanes to provide the desired product. C 19 H 23 LC-MS calculated for BrClN4O3 (M+H) + : m / z = 469.1 / 471.1: Experimen tal value 469.1 / 471.1.
[0365] Step 4: tert-Butyl 2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate
[0366]
[0367] A mixture of tert-butyl 2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Step 3: 1.0 g, 2.129 mmol), 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bis[[1,3,2]dioxaborolanyl] (0.649 g, 2.55 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with dichloromethane (1:1) (0.174 g, 0.213 mmol) and potassium acetate (0.522 g, 5.32 mmol) in 1,4-dioxane (24.0 mL) was purged with nitrogen and then stirred at 110 °C for 3 h. The reaction mixture was cooled to room temperature, diluted with dichloromethane, and then filtered through celite. The filtrate was concentrated under reduced pressure, and the residue was purified by flash chromatography on a silica gel column eluting with 0-30% ethyl acetate / hexanes to provide the desired product. 25 H 35 LC-MS calculated value of BClN4O5 (M+H) + : m / z = 517.2: Experimen tal value 517.2.
[0368] Step 5: 2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester
[0369]
[0370] A mixture of tert-butyl 2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Step 3: 900 mg, 1.92 mmol) in trifluoroacetic acid (4.0 mL) and dichloromethane (8.0 mL) was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure. A mixture of the above residue, tert-butyl 2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Step 4: 1188 mg, 2.30 mmol), sodium carbonate (1015 mg, 9.58 mmol), and [1,1-bis(di-cyclohexylphosphino)ferrocene]dichloropalladium(II) (145 mg, 0.19 mmol) in 1,4-dioxane (12.0 mL) and water (6.0 mL) was purged with nitrogen and then stirred at 110° C. for 2 h. After cooling to room temperature, the reaction mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0-10% methanol / dichloromethane to provide the desired product. 33 H 37 LC-MS calculated for Cl2N8O4 (M+H) + : m / z = 679.2: Experimen tal value 679.2.
[0371] Step 6: 4-Formylbicyclo[2.2.1]heptane-1-carboxylic acid methyl ester
[0372]
[0373] A mixture of 4-(hydroxymethyl)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester (PharmaBlock, catalog number PBZ3820: 400 mg, 2.17 mmol) and Dess-Martin periodinane (1381 mg, 3.26 mmol) in dichloromethane (12.0 mL) was stirred at room temperature for 2 h. The reaction mixture was quenched with 20% Na2S2O3 aqueous solution and saturated NaHCO3 aqueous solution and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was used directly in the next step without further purification.
[0374] Step 7: 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester
[0375]
[0376] Potassium tert-butoxide in THF (1.0 M, 4.39 mL, 4.39 mmol) was added to a suspension of chloro(methoxymethyl)triphenylphosphine (1505 mg, 4.39 mmol) in tetrahydrofuran (12.0 mL). The reaction mixture was stirred at room temperature for 1 h, and then 4-formylbicyclo[2.2.1]heptane-1-carboxylic acid methyl ester (step 6: 400 mg, 2.195 mmol) was added. After stirring at room temperature for 5 h, the reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in tetrahydrofuran (12.0 mL) and then treated with aqueous HCl (4.0 M, 11 mL, 43.9 mmol) at room temperature for 1 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was used directly in the next step without further purification.
[0377] Step 8: 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester
[0378]
[0379] Methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Step 7: 43.3 mg, 0.221 mmol) was added to a mixture of tert-butyl 2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Step 5: 100 mg, 0.147 mmol) and sodium triacetoxyborohydride (94 mg, 0.441 mmol) in dichloromethane (1.5 mL). After stirring at room temperature for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was treated with dichloromethane (1.0mL) and trifluoroacetic acid (0.5mL) for 1h at room temperature. The reaction mixture was concentrated under reduced pressure. The residue was treated with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column, eluted with 0-10% methanol / dichloromethane to provide the desired product. 39 H 45 LC-MS calculated for Cl2N8O4 (M+H) + : m / z = 759.3: Experimen tal value 759.3.
[0380] Step 9: 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0381] Lithium hydroxide monohydrate (11.1 mg, 0.263 mmol) was added to a solution of methyl 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Step 8: 40 mg, 0.053 mmol) in THF / MeOH / water (0.2 mL / 0.2 mL / 0.1 mL). After stirring at 30° C. for 3 h, the reaction mixture was diluted with MeOH and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. 38 H 43 LC-MS calculated for Cl2N8O4 (M+H) + : m / z = 745.3: Experimen tal value 745.3. 1 H NMR (600MHz, DMSO-d6) δ9.93 (s, 2H), 9.49 (s, 1H), 8.29 (dd, J = 8.2, 1.3Hz, 1H), 8.28 (dd, J =8.2,1.3Hz,1H),7.51(t,J=8.0Hz,2H),7.18(d,J=7.5,2H),4.55–4.44(m,1H),4.28–4.15 (m,3H),3.95(s,3H),3.95(s,3H),3.87–3.78(m,1H),3.54–3.38(m,3H),3.32–3.20(m,2H) ,3.18–2.92(m,4H),2.04–1.82(m,4H),1.58–1.48(m,4H),1.45(s,2H),1.42–1.32(m,2H).
[0382] Example 2
[0383] 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0384]
[0385] Tetrahydro-4H-pyran-4-one (2.6 mg, 0.026 mmol) was added to a mixture of methyl 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 8: 10 mg, 0.013 mmol) and sodium triacetoxyborohydride (8.4 mg, 0.039 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1 mL / 0.1 mL / 0.05 mL) and treated with lithium hydroxide monohydrate (2.8 mg, 0.066 mmol). After stirring at 30 ° C for 3 h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH = 2, acetonitrile / water + TFA) to obtain the desired product in the form of a TFA salt. C 43 H 51 LC-MS calculated value of Cl2N8O5 (M+H) + : m / z = 829.3: Experimen tal value 829.4. 1 H NMR(500MHz,DMSO-d6)δ9.93(s,1H),9.92(s,1H),8.31(dd,J=8.4,1.4Hz,1H),8.29(dd,J=8.4, 1.4Hz,1H),7.51(t,J=7.7Hz,2H),7.18(d,J=7.6,1H),7.18(d,J=7.6,1H),4.56–4.18(m,4H),4 .04–3.97(m,2H),3.96(s,3H),3.95(s,3H),3.95–3.78(m,2H),3.68–3.56(m,1H),3.50–3.20(m ,6H),3.15–2.94(m,4H),2.13–1.70(m,8H),1.59–1.48(m,4H),1.46(s,2H),1.42–1.32(m,2H).
[0386] Table 1. The compounds in Table 1 were prepared according to the synthetic scheme described in Example 2 using appropriate starting materials.
[0387]
[0388]
[0389]
[0390]
[0391] Example 13
[0392] (R)-4-(2-(2-((2,2'-dichloro-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0393]
[0394] (R)-2-((tert-Butyldimethylsilyl)oxy)propanal (5.0 mg, 0.026 mmol) was added to a mixture of methyl 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 8: 10 mg, 0.013 mmol) and sodium triacetoxyborohydride (8.4 mg, 0.039 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with a saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (0.10mL) and then treated with a 1,4-dioxane solution of HCl (4.0M, 65.8μL, 0.263mmol) for 2h at 40°C. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and then treated with monohydrated lithium hydroxide (5.5mg, 0.132mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. C 41 H 49 LC-MS calculated value of Cl2N8O5 (M+H) +: m / z = 803.3: Experimen tal value 803.3. 1 H NMR(600MHz, DMSO-d6)δ9.93(s,2H),8.32–8.25(m,2H),7.51(t,J=7.9Hz,2H),7.18(d,J=7.6,2H),5.53(br,1H),4.55–4.12(m,5H),3.9 5(s,3H),3.95(s,3H),3.87–2.92(m,12H),2.04–1.82(m,4H),1.58–1.47(m,4H),1.46(s,2H),1.42–1.32(m,2H),1.13(d,J=6.1Hz,3H).
[0395] Table 2. The compounds in Table 2 were prepared according to the synthetic scheme described in Example 13 using appropriate starting materials.
[0396]
[0397]
[0398] Embodiment 17
[0399] 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid)
[0400]
[0401] To a mixture of methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 7: 5.2 mg, 0.026 mmol) was added methyl 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 8: 10 mg, 0.013 mmol) and sodium triacetoxyborohydride (8.37 mg, 0.039 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and treated with monohydrated lithium hydroxide (5.5mg, 0.132mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. 48 H 57 LC-MS calculated for Cl2N8O6 (M+H) + : m / z = 911.4: Experimen tal value 911.4. 1 H NMR(600MHz,DMSO-d6)δ12.08(s,2H),9.93(s,2H),8.29(d,J=8.1Hz,2H), 7.51(t,J=7.9Hz,2H),7.18(d,J=7.7Hz,2H),4.56–4.44(m,2H),4.30–4.18 (m,2H),3.95(s,6H),3.87–3.78(m,2H),3.52–3.20(m,6H),3.14–2.94(m, 4H),2.04–1.82(m,8H),1.58–1.48(m,8H),1.46(s,4H),1.42–1.32(m,4H).
[0402] Table 3. The compounds in Table 3 were prepared according to the synthetic scheme described in Example 17 using appropriate starting materials.
[0403]
[0404]
[0405]
[0406] Embodiment 27
[0407] 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0408]
[0409] Step 1: tert-Butyl 2-((3-bromo-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate
[0410]
[0411] Potassium tert-butoxide in THF (1.0 M, 13.54 mL, 13.54 mmol) was added to a solution of 5-tert-butyl 2-methyl 1-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridine-2,5(4H)-dicarboxylate (Example 1, Step 2: 2.00 g, 6.77 mmol) and 3-bromo-2-methylaniline (1.26 g, 6.77 mmol) in tetrahydrofuran (34.0 mL). After stirring at room temperature for 30 min, the reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0-50% ethyl acetate / hexanes to provide the desired product. C 20 H 26 LC-MS calculated for BrN4O3 (M+H) + : m / z = 449.1 / 451.1: Experimen tal value 449.1 / 451.1.
[0412] Step 2: tert-Butyl 1-methyl-2-((2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamoyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate
[0413]
[0414] A mixture of tert-butyl 2-((3-bromo-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Step 1: 600 mg, 1.34 mmol), 4,4,5,5,4',4',5',5'-octamethyl-[2,2']bis[[1,3,2]dioxaborolanyl] (509 mg, 2.00 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (109 mg, 0.14 mmol) complexed with dichloromethane (1:1) and potassium acetate (393 mg, 4.01 mmol) in 1,4-dioxane (13.0 mL) was purged with nitrogen and then stirred at 100° C. for 2 h. The reaction mixture was cooled to room temperature, diluted with dichloromethane, and filtered through celite. The filtrate was concentrated and the residue was purified by flash chromatography on a silica gel column eluting with 0-30% ethyl acetate / hexanes to provide the desired product. 26 H 38 LC-MS calculated value of BN4O5 (M+H) + : m / z = 497.3: Experimen tal value 497.3.
[0415] Step 3: tert-Butyl 2-((2'-chloro-2-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate
[0416]
[0417] A solution of tert-butyl 2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 1, Step 3: 1.0 g, 2.129 mmol) in dichloromethane (8.0 mL) and trifluoroacetic acid (4.0 mL) was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure. A mixture of the above residue, tert-butyl 1-methyl-2-((2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamoyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Step 2: 1.162 g, 2.342 mmol), sodium carbonate (1.128 g, 10.64 mmol), and [1,1-bis(di-cyclohexylphosphino)ferrocene]dichloropalladium(II) (0.161 g, 0.213 mmol) in 1,4-dioxane (12.0 mL) and water (6.0 mL) was purged with nitrogen and then stirred at 110° C. for 2 h. After cooling to room temperature, the reaction mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0-10% methanol / dichloromethane to provide the desired product. 34 H 40 LC-MS calculated for ClN8O4 (M+H) + : m / z = 659.3: Experimen tal value 659.4.
[0418] Step 4: 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester
[0419]
[0420] Methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 7: 44.7 mg, 0.228 mmol) was added to a mixture of tert-butyl 2-((2'-chloro-2-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Step 3: 100 mg, 0.152 mmol) and sodium triacetoxyborohydride (96 mg, 0.455 mmol) in dichloromethane (1.5 mL). After stirring at room temperature for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was treated with dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 mL) for 1 h at room temperature. The mixture was concentrated under reduced pressure. The residue was treated with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column, eluted with 0-10% methanol / dichloromethane to provide the desired product. 40 H 48 LC-MS calculated for ClN8O4 (M+H) + : m / z = 739.3: Experimen tal value 739.3.
[0421] Step 5: 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0422] Lithium hydroxide monohydrate (2.8 mg, 0.068 mmol) was added to a solution of methyl 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Step 4: 10 mg, 0.014 mmol) in THF / MeOH / water (0.1 mL / 0.1 mL / 0.05 mL). After stirring at 30° C. for 3 h, the reaction mixture was diluted with MeOH and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. 39 H 46 LC-MS calculated for ClN8O4 (M+H) + : m / z = 725.3: Experimen tal value 725.3.
[0423] Embodiment 28
[0424] 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0425]
[0426] Tetrahydro-4H-pyran-4-one (2.7 mg, 0.027 mmol) was added to a mixture of methyl 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 27, Step 4: 10 mg, 0.014 mmol) and sodium triacetoxyborohydride (8.6 mg, 0.041 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and treated with monohydrated lithium hydroxide (2.8mg, 0.068mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. 44 H 54 LC-MS calculated value of ClN8O5 (M+H) + : m / z = 809.4: Experimen tal value 809.4.
[0427] Table 4. The compounds in Table 4 were prepared according to the synthetic scheme described in Example 28 using appropriate starting materials.
[0428]
[0429] Embodiment 31
[0430] (R)-4-(2-(2-((2-chloro-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0431]
[0432] (R)-2-((tert-Butyldimethylsilyl)oxy)propanal (5.1 mg, 0.027 mmol) was added to a mixture of methyl 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 27, Step 4: 10 mg, 0.014 mmol) and sodium triacetoxyborohydride (8.6 mg, 0.041 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with a saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (0.10mL) and then treated with a 1,4-dioxane solution of HCl (4.0M, 67.6μL, 0.271mmol) for 2h at 40°C. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and then treated with monohydrated lithium hydroxide (5.7mg, 0.135mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. C 42 H 52 LC-MS calculated value of ClN8O5 (M+H) + : m / z = 783.4: Experimen tal value 783.4. 1 H NMR (600MHz, DMSO-d6) δ9.94 (s, 1H), 9.91 (s, 1H), 8.25 (d, J = 8.1Hz, 1H), 7.62 (t, J = 8.3Hz, 1H),7.48(t,J=7.9Hz,1H),7.32(t,J=7.8Hz,1H),7.11(dd,J=7.5,1.4Hz,1H),7.04(d,J=7 .5Hz,1H)5.55(br,1H),4.55–4.14(m,5H),3.95(s,3H),3.91(s,3H),3.88–2.95(m,12H),2 .04–1.82(m,7H),1.58–1.47(m,4H),1.46(s,2H),1.42–1.32(m,2H),1.14(d,J=6.0Hz,3H).
[0433] Table 5. The compounds in Table 5 were prepared according to the synthetic scheme described in Example 31 using appropriate starting materials.
[0434]
[0435] Embodiment 34
[0436] 4,4'-(((((2-chloro-2'-methyl-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid)
[0437]
[0438] To a mixture of methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 7: 5.3 mg, 0.027 mmol) was added methyl 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 27, Step 4: 10 mg, 0.014 mmol) and sodium triacetoxyborohydride (8.6 mg, 0.041 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and then treated with monohydrated lithium hydroxide (5.7mg, 0.135mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. 49 H 60 LC-MS calculated for ClN8O6 (M+H) + : m / z = 891.4: Experimen tal value 891.4.
[0439] Table 6. The compounds in Table 6 were prepared according to the synthetic scheme described in Example 34 using appropriate starting materials.
[0440]
[0441] Embodiment 37
[0442] 4-(2-(2-((2'-chloro-2-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0443]
[0444] Step 1: tert-Butyl 2-((2-chloro-2'-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate
[0445]
[0446] A solution of tert-butyl 1-methyl-2-((2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamoyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 27, Step 2: 254 mg, 0.511 mmol) in dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 mL) was stirred at room temperature for 30 min. The reaction mixture was concentrated under reduced pressure. The residue, tert-butyl 2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 1, Step 3: 200 mg, 0.426 mmol), sodium carbonate (226 mg, 2.129 mmol) and a mixture of [1,1-bis(di-cyclohexylphosphino)ferrocene]dichloropalladium(II) (32.3 mg, 0.043 mmol) in 1,4-dioxane (2.0 mL) and water (2.0 mL) were purged with nitrogen and then stirred at 110° C. for 2 h. After cooling to room temperature, the reaction mixture was diluted with water and extracted with dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0-10% methanol / dichloromethane to provide the desired product. 34 H 40 LC-MS calculated for ClN8O4 (M+H) +: m / z = 659.3: Experimen tal value 659.3.
[0447] Step 2: 4-(2-(2-((2'-chloro-2-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester
[0448]
[0449] Methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 7: 44.7 mg, 0.228 mmol) was added to a mixture of tert-butyl 2-((2-chloro-2'-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Step 1: 100 mg, 0.152 mmol) and sodium triacetoxyborohydride (96 mg, 0.455 mmol) in dichloromethane (1.5 mL). After stirring at room temperature for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was treated with dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 mL) for 1 h at room temperature. The mixture was concentrated under reduced pressure. The residue was treated with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column, eluted with 0-10% methanol / dichloromethane to provide the desired product. 40 H 48 LC-MS calculated for ClN8O4 (M+H) + : m / z = 739.3: Experimen tal value 739.3.
[0450] Step 3: 4-(2-(2-((2'-chloro-2-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0451] Lithium hydroxide monohydrate (2.8 mg, 0.068 mmol) was added to a solution of methyl 4-(2-(2-((2'-chloro-2-methyl-3'-(l-methyl-4,5,6,7-tetrahydro-lH-imidazo[4,5-c]pyridine-2-carboxamido)-[l,l'-biphenyl]-3-yl)carbamoyl)-l-methyl-l,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-l-carboxylate (Step 2: 10.0 mg, 0.014 mmol) in THF / MeOH / water (0.1 mL / 0.1 mL / 0.05 mL). After stirring at 30° C. for 3 h, the reaction mixture was diluted with MeOH and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. 39 H 46 LC-MS calculated for ClN8O4 (M+H) + : m / z = 725.3: Experimen tal value 725.3.
[0452] Embodiment 38
[0453] 4-(2-(2-((2'-chloro-2-methyl-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0454]
[0455] Tetrahydro-4H-pyran-4-one (2.7 mg, 0.027 mmol) was added to a mixture of methyl 4-(2-(2-((2'-chloro-2-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 37, Step 2: 10.0 mg, 0.014 mmol) and sodium triacetoxyborohydride (8.6 mg, 0.041 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and treated with monohydrated lithium hydroxide (2.8mg, 0.068mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. 44 H 54 LC-MS calculated value of ClN8O5 (M+H) + : m / z = 809.4: Experimen tal value 809.4.
[0456] Table 7. The compounds in Table 7 were prepared according to the synthetic scheme described in Example 38 using appropriate starting materials.
[0457]
[0458] Embodiment 41
[0459] (R)-4-(2-(2-((2'-chloro-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0460]
[0461] (R)-2-((tert-Butyldimethylsilyl)oxy)propanal (5.1 mg, 0.027 mmol) was added to a mixture of methyl 4-(2-(2-((2'-chloro-2-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 37, Step 2: 10 mg, 0.014 mmol) and sodium triacetoxyborohydride (8.6 mg, 0.041 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with a saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (0.10mL) and then treated with a 1,4-dioxane solution of HCl (4.0M, 67.6μL, 0.271mmol) for 2h at 40°C. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and then treated with monohydrated lithium hydroxide (5.7mg, 0.135mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. C 42 H 52 LC-MS calculated value of ClN8O5 (M+H) + : m / z = 783.4: Experimen tal value 783.4.
[0462] Table 8. The compounds in Table 8 were prepared according to the synthetic scheme described in Example 41 using appropriate starting materials.
[0463]
[0464]
[0465] Embodiment 44
[0466] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chloro-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0467]
[0468] To a mixture of methyl 4-(2-(2-((2'-chloro-2-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 37, Step 2: 10 mg, 0.014 mmol) and sodium triacetoxyborohydride (8.6 mg, 0.041 mmol) in dichloromethane (0.20 mL) was added methyl 4-formylbicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 6: 4.9 mg, 0.027 mmol). After stirring at room temperature for 2h, the reaction mixture was quenched with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and then treated with monohydrated lithium hydroxide (5.7mg, 0.135mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. 48 H 58 LC-MS calculated for ClN8O6 (M+H) + : m / z = 877.4: Experimen tal value 877.4.
[0469] Table 9. The compounds in Table 9 were prepared according to the synthetic scheme described in Example 44 using appropriate starting materials.
[0470]
[0471] Embodiment 46
[0472] 4-(2-(2-((2-chloro-2'-cyano-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0473]
[0474] Step 1: tert-Butyl 2-((3-bromo-2-cyanophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate
[0475]
[0476] Potassium tert-butoxide in THF (1.0 M, 0.677 mL, 0.677 mmol) was added to a solution of 5-tert-butyl 2-methyl 1-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridine-2,5(4H)-dicarboxylate (Example 1, Step 2: 100 mg, 0.339 mmol) and 2-amino-6-bromobenzonitrile (66.7 mg, 0.339 mmol) in tetrahydrofuran (3.0 mL). After stirring at room temperature for 30 min, the reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0-50% ethyl acetate / hexane to provide the desired product. C 20 H 23 LC-MS calculated for BrN5O3 (M+H) + : m / z = 460.1 / 462.1: Experimen tal value 460.2 / 462.2.
[0477] Step 2: 2-((2'-chloro-2-cyano-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester
[0478]
[0479] A mixture of tert-butyl 2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 1, Step 4: 1078 mg, 2.085 mmol) in trifluoroacetic acid (2.0 mL) and dichloromethane (4.0 mL) was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure. A mixture of the above residue, tert-butyl 2-((3-bromo-2-cyanophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Step 1: 800 mg, 1.738 mmol), sodium carbonate (921 mg, 8.69 mmol), and [1,1-bis(di-cyclohexylphosphino)ferrocene]dichloropalladium(II) (132 mg, 0.174 mmol) in 1,4-dioxane (12.0 mL) and water (6.0 mL) was purged with nitrogen and then stirred at 110° C. for 3 h. After cooling to room temperature, the reaction mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0-10% methanol / dichloromethane to provide the desired product. C 34 H 37 LC-MS calculated for ClN9O4 (M+H) + : m / z = 670.3: Experimen tal value 670.4.
[0480] Step 3: 4-(2-(2-((2-chloro-2'-cyano-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester
[0481]
[0482] Methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 7: 43.9 mg, 0.224 mmol) was added to a mixture of tert-butyl 2-((2'-chloro-2-cyano-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Step 2: 100 mg, 0.149 mmol) and sodium triacetoxyborohydride (95 mg, 0.458 mmol) in dichloromethane (1.5 mL). After stirring at room temperature for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was treated with dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 mL) for 1 h at room temperature. The mixture was concentrated under reduced pressure. The residue was treated with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column, eluted with 0-10% methanol / dichloromethane to provide the desired product. 40 H 45 LC-MS calculated for ClN9O4 (M+H) + : m / z = 750.3: Experimen tal value 750.3.
[0483] Step 4: 4-(2-(2-((2-chloro-2'-cyano-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0484] Lithium hydroxide monohydrate (2.8 mg, 0.067 mmol) was added to a solution of methyl 4-(2-(2-((2-chloro-2'-cyano-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Step 3: 10 mg, 0.013 mmol) in THF / MeOH / water (0.1 mL / 0.1 mL / 0.05 mL). After stirring at 30° C. for 3 h, the reaction mixture was diluted with MeOH and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. 39 H 43 LC-MS calculated for ClN9O4 (M+H) + : m / z = 736.3: Experimen tal value 736.3.
[0485] Embodiment 47
[0486] 4-(2-(2-((2-chloro-2'-cyano-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0487]
[0488] Tetrahydro-4H-pyran-4-one (2.7 mg, 0.027 mmol) was added to a mixture of methyl 4-(2-(2-((2-chloro-2'-cyano-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 46, Step 3: 10 mg, 0.013 mmol) and sodium triacetoxyborohydride (8.5 mg, 0.040 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and treated with monohydrated lithium hydroxide (2.8mg, 0.067mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. 44 H 51 LC-MS calculated value of ClN9O5 (M+H) + : m / z = 820.4: Experimen tal value 820.4.
[0489] Table 10. The compounds in Table 10 were prepared according to the synthetic scheme described in Example 47 using appropriate starting materials.
[0490]
[0491]
[0492] Embodiment 49
[0493] (R)-4-(2-(2-((2-chloro-2'-cyano-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0494]
[0495] (R)-2-((tert-Butyldimethylsilyl)oxy)propanal (5.0 mg, 0.027 mmol) was added to a mixture of methyl 4-(2-(2-((2-chloro-2'-cyano-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 46, Step 3: 10 mg, 0.013 mmol) and sodium triacetoxyborohydride (8.5 mg, 0.040 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with a saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (0.10mL) and then treated with a 1,4-dioxane solution of HCl (4.0M, 66.6μL, 0.267mmol) for 2h at 40°C. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and then treated with monohydrated lithium hydroxide (5.6mg, 0.133mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. C 42 H 49 LC-MS calculated value of ClN9O5 (M+H) + : m / z = 794.4: Experimen tal value 794.4.
[0496] Table 11. The compounds in Table 11 were prepared according to the synthetic scheme described in Example 49 using appropriate starting materials.
[0497]
[0498] Embodiment 51
[0499] 4,4'-(((((2-chloro-2'-cyano-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid)
[0500]
[0501] To a mixture of methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 7: 5.2 mg, 0.027 mmol) was added methyl 4-(2-(2-((2-chloro-2'-cyano-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 46, Step 3: 10 mg, 0.013 mmol) and sodium triacetoxyborohydride (8.5 mg, 0.040 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and then treated with monohydrated lithium hydroxide (5.6mg, 0.133mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. 49 H 57 LC-MS calculated value of ClN9O6 (M+H) + : m / z = 902.4: Experimen tal value 902.5.
[0502] Table 12. The compounds in Table 12 were prepared according to the synthetic scheme described in Example 51 using appropriate starting materials.
[0503]
[0504]
[0505] Embodiment 53
[0506] 4-(2-(2-((2,2'-dimethyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0507]
[0508] Step 1: 2-((2,2'-dimethyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester
[0509]
[0510] A mixture of tert-butyl 2-((3-bromo-2-methylphenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 27, Step 1: 100 mg, 0.223 mmol) in trifluoroacetic acid (1.0 mL) and dichloromethane (2.0 mL) was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure. A mixture of the above residue, tert-butyl 1-methyl-2-((2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamoyl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 27, Step 2: 133 mg, 0.267 mmol), sodium carbonate (118 mg, 1.113 mmol) and [1,1-bis(di-cyclohexylphosphino)ferrocene]dichloropalladium(II) (16.9 mg, 0.022 mmol) in 1,4-dioxane (1.4 mL) and water (0.7 mL) was purged with nitrogen and then stirred at 110° C. for 2 h. After cooling to room temperature, the reaction mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0-10% methanol / dichloromethane to provide the desired product. 35 H 43 LC-MS calculated for N8O4 (M+H) + : m / z = 639.3: Experimen tal value 639.3.
[0511] Step 2: 4-(2-(2-((2,2'-dimethyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester
[0512]
[0513] Methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 7: 46.1 mg, 0.235 mmol) was added to a mixture of tert-butyl 2-((2,2'-dimethyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Step 1: 100 mg, 0.157 mmol) and sodium triacetoxyborohydride (100 mg, 0.470 mmol) in dichloromethane (1.5 mL). After stirring at room temperature for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was treated with dichloromethane (1.0 mL) and trifluoroacetic acid (0.5 mL) for 1 h at room temperature. The mixture was concentrated under reduced pressure. The residue was treated with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column, eluted with 0-10% methanol / dichloromethane to provide the desired product. 41 H 51 LC-MS calculated for N8O4 (M+H) + : m / z = 719.4: Experimen tal value 719.4.
[0514] Step 3: 4-(2-(2-((2,2'-dimethyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0515] Lithium hydroxide monohydrate (2.9 mg, 0.070 mmol) was added to a solution of methyl 4-(2-(2-((2,2'-dimethyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Step 2: 10 mg, 0.014 mmol) in THF / MeOH / water (0.1 mL / 0.1 mL / 0.05 mL). After stirring at 30° C. for 3 h, the reaction mixture was diluted with MeOH and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt. 40 H 49 LC-MS calculated for N8O4 (M+H) + : m / z = 705.4: Experimen tal value 705.4.
[0516] Embodiment 54
[0517] 4,4'-(((((2,2'-dimethyl-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid)
[0518]
[0519] To a mixture of methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 7: 5.5 mg, 0.028 mmol) was added methyl 4-(2-(2-((2,2'-dimethyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 53, Step 2: 10 mg, 0.014 mmol) and sodium triacetoxyborohydride (8.8 mg, 0.042 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and then treated with monohydrated lithium hydroxide (5.8mg, 0.139mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. 50 H 63 LC-MS calculated for N8O6 (M+H) + : m / z = 871.5: Experimen tal value 871.5.
[0520] Table 13. The compounds in Table 13 were prepared according to the synthetic scheme described in Example 54 using appropriate starting materials.
[0521]
[0522]
[0523] Embodiment 57
[0524] (R)-4-(2-(2-((3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0525]
[0526] (R)-2-((tert-Butyldimethylsilyl)oxy)propanal (5.2 mg, 0.028 mmol) was added to a mixture of methyl 4-(2-(2-((2,2'-dimethyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 53, Step 2: 10 mg, 0.014 mmol) and sodium triacetoxyborohydride (8.5 mg, 0.040 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with a saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (0.10mL) and then treated with a 1,4-dioxane solution of HCl (4.0M, 69.6μL, 0.278mmol) for 2h at 40°C. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and then treated with monohydrated lithium hydroxide (5.8mg, 0.139mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. C 43 H 55 LC-MS calculated for N8O5 (M+H) + : m / z = 763.4: Experimen tal value 763.4.
[0527] Table 14. The compounds in Table 14 were prepared according to the synthetic scheme described in Example 57 using appropriate starting materials.
[0528]
[0529]
[0530] Embodiment 60
[0531] 4-(2-(2-((2,2'-dichloro-3'-(5-(4-hydroxycyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0532]
[0533] Step 1: 4-(2-(2-((2,2'-dichloro-3'-(5-(4-hydroxycyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester
[0534]
[0535] 4-Hydroxycyclohexan-1-one (6.0 mg, 0.053 mmol) was added to a mixture of methyl 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 8: 20 mg, 0.026 mmol) and sodium triacetoxyborohydride (16.7 mg, 0.079 mmol) in dichloromethane (0.30 mL). After stirring at room temperature for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by preparative-HPLC (pH=10, acetonitrile / water+NH4OH) to give two desired products (cis / trans isomers).
[0536] Peak 1: Retention time t on analytical LC-MS (pH=10, acetonitrile / water+NH4OH) r =1.71min, C 45 H 55 LC-MS calculated value of Cl2N8O5 (M+H) + :m / z=857.4: Experimen tal value: 857.4.
[0537] Peak 2: Retention time t on analytical LC-MS (pH=10, acetonitrile / water+NH4OH) r =1.73min, C 45 H 55 LC-MS calculated value of Cl2N8O5 (M+H) + : m / z = 857.4: Exp. value: 857.4;
[0538] Step 2: 4-(2-(2-((2,2'-dichloro-3'-(5-(4-hydroxycyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0539] Methyl 4-(2-(2-((2,2'-dichloro-3'-(5-(4-hydroxycyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (5 mg, 5.83 μmol) from step 1, peak 1 and peak 2 were treated separately with lithium hydroxide monohydrate (1.3 mg, 0.030 mmol) in THF / MeOH / water (0.1 mL / 0.1 mL / 0.05 mL) at 30 °C for 2 h. The reaction was purified by prep-HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt.
[0540] Compound 1 (from step 1, peak 1): C 44 H 53 LC-MS calculated value of Cl2N8O5 (M+H) + :m / z=843.4: Experimen tal value: 843.4.
[0541] Compound 2 (from step 1, peak 2): C 44 H 53 LC-MS calculated value of Cl2N8O5 (M+H) + :m / z=843.4: Experimen tal value: 843.4.
[0542] Embodiment 61
[0543] 4-(2-(2-((2-chloro-3'-(5-(4-hydroxycyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0544]
[0545] Step 1: 4-(2-(2-((2-chloro-3'-(5-(4-hydroxycyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester
[0546]
[0547] 4-Hydroxycyclohexan-1-one (6.2 mg, 0.054 mmol) was added to a mixture of methyl 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 27, Step 4: 20 mg, 0.027 mmol) and sodium triacetoxyborohydride (17.2 mg, 0.081 mmol) in dichloromethane (0.30 mL). After stirring at room temperature for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by preparative-HPLC (pH=10, acetonitrile / water+NH4OH) to give two desired products (cis / trans isomers).
[0548] Peak 1: Retention time t on analytical LC-MS (pH=10, acetonitrile / water+NH4OH) r =1.62min, C 46 H 58 LC-MS calculated value of ClN8O5 (M+H) + :m / z=837.4: Experimen tal value: 837.4.
[0549] Peak 2: Retention time t on analytical LC-MS (pH=10, acetonitrile / water+NH4OH) r =1.64min, C 46 H 58 LC-MS calculated value of ClN8O5 (M+H) + :m / z=837.4: Experimen tal value: 837.4.
[0550] Step 2: 4-(2-(2-((2-chloro-3'-(5-(4-hydroxycyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0551] Methyl 4-(2-(2-((2-chloro-3'-(5-(4-hydroxycyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (5 mg, 5.97 μmol) from step 1, peak 1 and peak 2 were treated separately with lithium hydroxide monohydrate (1.3 mg, 0.030 mmol) in THF / MeOH / water (0.1 mL / 0.1 mL / 0.05 mL) at 30 °C for 2 h. The reaction was purified by prep-HPLC (pH=2, acetonitrile / water+TFA) to give the desired product as a TFA salt.
[0552] Compound 1 (from step 1, peak 1): C 45 H 56 LC-MS calculated value of ClN8O5 (M+H) + :m / z=823.4: Experimen tal value: 823.4.
[0553] Compound 2 (from step 1, peak 2): C 45 H 56 LC-MS calculated value of ClN8O5 (M+H) + :m / z=823.4: Experimen tal value: 823.4.
[0554] Embodiment 62
[0555] 4-(2-(2-((3'-(5-(2-(trans-4-carboxycyclohexyl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0556]
[0557] Methyl 4-(2-oxoethyl)cyclohexane-1-carboxylate (4.9 mg, 0.026 mmol) was added to a mixture of methyl 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 8: 10 mg, 0.013 mmol) and sodium triacetoxyborohydride (8.4 mg, 0.039 mmol) in dichloromethane (0.2 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and treated with monohydrated lithium hydroxide (5.5mg, 0.132mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product (main peak) in the form of a TFA salt. 47 H 57 LC-MS calculated for Cl2N8O6 (M+H) + : m / z = 899.4: Experimen tal value 899.4.
[0558] Embodiment 63
[0559] 4-(2-(2-((3'-(5-(4-carboxybutyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0560]
[0561] Step 1: 4-(2-(2-((3'-(5-(5-(tert-butoxy)-5-oxopentyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid methyl ester
[0562]
[0563] Tert-butyl 5-oxopentanoate (34.0 mg, 0.197 mmol) was added to a mixture of methyl 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 8: 100 mg, 0.132 mmol) and sodium triacetoxyborohydride (84 mg, 0.395 mmol) in dichloromethane (1.2 mL). After stirring at room temperature for 2 h, the reaction mixture was quenched with saturated aqueous NaHCO3 and extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0-10% methanol / dichloromethane to provide the desired product. 48 H 61 LC-MS calculated for Cl2N8O6 (M+H) + : m / z = 915.4: Experimen tal value 915.5.
[0564] Step 2: 4-(2-(2-((3'-(5-(4-carboxybutyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0565] A solution of methyl 4-(2-(2-((3'-(5-(5-(tert-butoxy)-5-oxopentyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Step 1: 10 mg, 10.9 μmol) in tetrahydrofuran (0.15 mL) was treated with HCl in 1,4-dioxane (4.0 M, 27.3 μL, 0.109 mmol) at 40° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1 mL / 0.1 mL / 0.05 mL) and treated with lithium hydroxide monohydrate (4.6 mg, 0.109 mmol). After stirring at 30°C for 3 h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH = 2, acetonitrile / water + TFA) to give the desired product in the form of a TFA salt. 43 H 51 LC-MS calculated for Cl2N8O6 (M+H) + : m / z = 845.3: Experimen tal value 845.3.
[0566] Embodiment 64
[0567] 4-(2-(2-((2,2'-dichloro-3'-(5-(5-(dimethylamino)-5-oxopentyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0568]
[0569] A solution of methyl 4-(2-(2-((3'-(5-(5-(tert-butoxy)-5-oxopentyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 63, Step 1: 10 mg, 10.9 μmol) in tetrahydrofuran (0.15 mL) was treated with HCl in 1,4-dioxane (4.0 M, 27.3 μL, 0.109 mmol) at 40° C. for 1 h. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in DMF (0.15 mL) and then subsequently treated with N,N-diisopropylethylamine (9.5 μL, 0.055 mmol), 3-oxido-1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridine hexafluorophosphate (8.3 mg, 0.022 mmol) and dimethylamine hydrochloride (1.4 mg, 0.016 mmol). After stirring at room temperature for 2 h, lithium hydroxide monohydrate (4.6 mg, 0.109 mmol) was added. The reaction mixture was stirred at 30 ° C for 3 h, then diluted with methanol and purified by pH 2 preparative LC / MS (MeCN / water plus TFA) to give the desired product. C 45 H 56 LC-MS calculated value of Cl2N9O5 (M+H) + : m / z = 872.4: Experimen tal value 872.4.
[0570] Embodiment 65
[0571] 4-(2-(2-((3'-(5-(cis-4-carboxy-4-methylcyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0572]
[0573] Step 1: 5-(cis-4-(tert-butoxycarbonyl)-4-methylcyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylic acid methyl ester
[0574] and
[0575] 5-(trans-4-(tert-Butyloxycarbonyl)-4-methylcyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylic acid methyl ester
[0576]
[0577] A solution of 5-tert-butyl 2-methyl 1-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridine-2,5(4H)-dicarboxylate (Example 1, Step 2: 0.50 g, 1.693 mmol) in dichloromethane (5.0 mL) and trifluoroacetic acid (5.0 mL) was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure. The residue was dissolved in dichloromethane (10.0 mL) and treated sequentially with N,N-diisopropylethylamine (0.89 mL, 5.08 mmol), sodium triacetoxyborohydride (0.72 g, 3.39 mmol) and tert-butyl 1-methyl-4-oxocyclohexane-1-carboxylate (1.1 g, 4.66 mmol). After stirring at room temperature for 2 h, the reaction was quenched with saturated aqueous NaHCO3 and extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0-10% methanol / dichloromethane to provide a mixture of cis / trans isomers, which were separated by a preparative chiral column (Phenomenex LUX 5um cellulose-4) eluting with 10% EtOH / hexanes to give the desired product.
[0578] Peak 1 (cis): retention time t r =20.1min, C 21 H 34 LC-MS calculated for N3O4 (M+H) + :m / z=392.3: Experimen tal value: 392.2. 1 H NMR (500MHz, CDCl3) δ3.92(s,3H),3.85(s,3H),3.66(s,2H),2.91(t,J=5.5Hz,2H),2.66(t,J=5.5Hz,2H),2 .62–2.52(m,1H),2.28–2.20(m,2H),1.86–1.77(m,2H),1.52–1.42(m,11H),1.21–1.14(m,2H),1.13(s,3H).
[0579] Peak 2 (trans): retention time t r =24.3min, C 21 H 34 LC-MS calculated for N3O4 (M+H)+ :m / z=392.3: Experimen tal value: 392.2. 1 H NMR (500MHz, CDCl3) δ3.92(s,3H),3.86(s,3H),3.68(s,2H),2.94(t,J=5.7Hz,2H),2.67(t,J=5.7Hz,2H),2.5 0(tt,J=10.6,3.5Hz,1H),1.83–1.76(m,2H),1.75–1.69(m,4H),1.64–1.52(m,2H),1.45(s,9H),1.18(s,3H).
[0580] Step 2: tert-Butyl cis-4-(2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1-methylcyclohexane-1-carboxylate
[0581]
[0582] Potassium tert-butoxide in THF (1.0 M, 0.56 mL, 0.56 mmol) was added to a solution of methyl 5-(cis-4-(tert-butoxycarbonyl)-4-methylcyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate (Step 1, Peak 1: 110 mg, 0.281 mmol) and 3-bromo-2-chloroaniline (58.0 mg, 0.281 mmol) in tetrahydrofuran (1.5 mL). After stirring at room temperature for 30 min, the reaction mixture was quenched with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0-50% ethyl acetate / hexanes to provide the desired product. C 26 H 35 LC-MS calculated for BrClN4O3 (M+H) + : m / z = 565.2 / 567.2: Experimen tal value 565.2 / 567.2.
[0583] Step 3: tert-Butyl cis-4-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1-methylcyclohexane-1-carboxylate
[0584]
[0585] A solution of tert-butyl 2-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate (Example 1, Step 4: 164 mg, 0.318 mmol) in trifluoroacetic acid (0.5 mL) and dichloromethane (1.0 mL) was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure. A mixture of the above residue, cis-tert-butyl 4-(2-((3-bromo-2-chlorophenyl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1-methylcyclohexane-1-carboxylate (Step 2: 150 mg, 0.265 mmol), sodium carbonate (140 mg, 1.325 mmol) and [dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (21.6 mg, 0.027 mmol) in 1,4-dioxane (1.6 mL) and water (0.8 mL) was purged with nitrogen and then stirred at 110° C. for 2 h. After cooling to room temperature, the reaction mixture was diluted with water and extracted with dichloromethane. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on a silica gel column eluting with 0-10% methanol / dichloromethane to provide the desired product. 40 H 49 LC-MS calculated for Cl2N8O4 (M+H) + : m / z = 775.3: Experimen tal value 775.4.
[0586] Step 4: 4-(2-(2-((3'-(5-(cis-4-carboxy-4-methylcyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0587] Methyl 4-(2-oxoethyl)bicyclo[2.2.1]heptane-1-carboxylate (Example 1, Step 7: 3.8 mg, 0.019 mmol) was added to a mixture of tert-butyl cis-4-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1-methylcyclohexane-1-carboxylate (Step 3: 10 mg, 0.013 mmol) and sodium triacetoxyborohydride (8.2 mg, 0.039 mmol) in dichloromethane (0.20 mL). After stirring at room temperature for 2h, the reaction mixture was quenched with a saturated NaHCO3 aqueous solution and extracted with dichloromethane. The combined organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in methanol (0.10mL) and then treated with a 1,4-dioxane solution of HCl (4.0M, 32μL, 0.129mmol) for 1h at 40°C. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in THF / MeOH / water (0.1mL / 0.1mL / 0.05mL) and then treated with monohydrated lithium hydroxide (5.4mg, 0.129mmol). After stirring at 30°C for 3h, the reaction mixture was diluted with methanol and purified by preparative-HPLC (pH=2, acetonitrile / water+TFA) to obtain the desired product in the form of a TFA salt. C 46 H 55 LC-MS calculated for Cl2N8O6 (M+H) + : m / z = 885.4: Experimen tal value 885.4.
[0588] Embodiment 66
[0589] 4-(2-(2-((3'-(5-(trans-4-carboxy-4-methylcyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid
[0590]
[0591] This compound was prepared using a procedure similar to that described for Example 65, substituting 5-(trans-4-(tert-butoxycarbonyl)-4-methylcyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylic acid methyl ester (from Example 65, Step 1, Peak 2) for 5-(cis-4-(tert-butoxycarbonyl)-4-methylcyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylic acid methyl ester in Step 2. The reaction mixture was diluted with methanol and then purified by pH 2 preparative LC / MS (MeCN / water plus TFA) to give the desired product as a TFA salt. 46 H 55 LC-MS calculated for Cl2N8O6 (M+H) + : m / z = 885.4: Experimen tal value 885.4.
[0592] Example A. Homogeneous Time-Resolved Fluorescence (HTRF) PD-1 / PD-L1 Binding Assay
[0593] The assay was performed in a standard black 384-well polystyrene plate with a final volume of 20 μL. The inhibitor was first serially diluted in DMSO and then added to the plate wells, followed by the addition of other reaction components. The final concentration of DMSO in the assay was 1%. The assay was performed at 25°C in PBS buffer (pH 7.4) containing 0.05% Tween-20 and 0.1% BSA. The recombinant human PD-L1 protein (19-238) with a His-tag at the C-terminus was purchased from AcroBiosystems (PD1-H5229). The recombinant human PD-1 protein (25-167) with an Fc tag at the C-terminus was also purchased from AcroBiosystems (PD1-H5257). PD-L1 and PD-1 proteins were diluted in assay buffer and 10 μL were added to the plate wells. The plate was centrifuged and the protein was pre-incubated for 40 minutes in the presence of the inhibitor. After incubation, 10 μL of HTRF detection buffer supplemented with europium cryptate-labeled anti-human IgG (PerkinElmer-AD0212) specific for Fc and bound to -Anti-His antibody to allophycocyanin (APC, PerkinElmer-AD0059H). After centrifugation, the plate was incubated at 25 ° C for 60 min. It was then read on a PHERAstar FS plate reader (665nm / 620nm ratio). The final concentrations in the analysis were -3nM PD1, 10nM PD-L1, 1nM Europium anti-human IgG and 20nM anti-His-allophycocyanin. IC was performed by fitting the curve of the percentage of control activity versus the logarithm of the inhibitor concentration using GraphPad Prism 5.0 software. 50 Determination.
[0594] Example B. Analysis of Src homology 2 domain containing phosphatase (SHP)
[0595] U2OS / PD-L1 cells (DiscoveRx Corporation) were maintained in McCoy's 5A medium supplemented with 10% FBS and 0.25 μg / ml puromycin. After the medium was removed, the cell culture medium was replaced with assay medium (RPMI1640 medium containing 1% FBS). U2OS / PD-L1 cells were then added to 384-well black clear bottom assay plates ( Tissue culture plates, Greiner Bio-One). Test compounds are prepared by serial dilution in DMSO, and first 125nL compounds are transferred to 384REMP plate wells (Thermofisher) by ECHO liquid handler (Labcyte), followed by addition of 27.5μL analysis culture medium. In the final analysis at 0.25μM, 5μL compounds per well in the analysis culture medium are transferred to the cell plate in the presence of 0.05% DMSO. Jurkat-PD-1-SHP cells (DiscoveRx Corporation) are cultivated in RPMI1640 culture medium supplemented with 10% FBS, 250μg / ml hygromycin B, 500μg / ml G418. After the culture medium is replaced with analysis culture medium, 20μL containing 5,000 Jurkat-PD-1-SHP cells are distributed in each well. The assay plate was incubated at 37°C, 5% CO2 for 2 hours, and then 2.5 μL PathHunter reagent 1 (DiscoveRx Corporation) was added to each well. The assay plate was shaken at 350 rpm in the dark for 1 min, followed by the addition of 10 μL PathHunter reagent 2 (DiscoveRx Corporation). Chemiluminescent signals were recorded using a TopCount reader (Perkin Elmer) after incubation for 1 hour at room temperature. Wells containing DMSO served as positive controls and wells without cells were used as negative controls. IC was performed by fitting a curve of control activity percentage versus the logarithm of compound concentration using GraphPad Prism 6.0 software. 50 Determination.
[0596] Example C. Analysis of Nuclear Factor of Activated T Cells (NFAT)
[0597] PD-L1 aAPC / CHO-K1 cells (Promega) were maintained in F-12 medium supplemented with 10% FBS, 200 μg / ml hygromycin B, 250 μg / ml geneticin (G418). Jurkat-PD-1-NFAT effector cells (Promega) were cultured in RPMI 1640 medium supplemented with 10% FBS, 100 μg / ml hygromycin B, 500 μg / ml G418. The culture medium of PD-L1aAPC / CHO-K1 cells was first replaced with assay medium (RPMI1640 medium containing 1% FBS). PD-L1 aAPC / CHO-K1 cells were then added to a white 384-well white transparent bottom assay plate ( Tissue culture plates, Greiner Bio-One). Test compounds were prepared by serial dilution in DMSO, and 0.8 μL of DMSO containing the test compound was first transferred to a 384REMP plate well (Thermofisher) by PlateMate Plus (Thermofisher), followed by the addition of 50 μL of plate culture medium. In the final analysis at 2 μM, 5 μL of assay culture medium containing the compound was transferred to the cells in the presence of 0.4% DMSO. After removing the culture medium, 5 μL of assay culture medium containing 10,000 Jurkat-PD-1-NFAT effector cells was distributed to each well. The assay plate was incubated at 37 ° C, 5% CO2 for 24 hours. After the assay plate was equilibrated at room temperature for 15 minutes, 20 μL / well of Bio-Glo TM The luminescence was read using a Pherastar microplate reader (BMG Labtech) and incubated for 8 minutes at room temperature. The luminescence ratio of each assay plate for the normalization of DMSO wells was used to calculate the induction factor (FOI). The maximum induction percentage was reported based on the ratio between the highest FOI of each compound and the maximum FOI of the control compound in each assay plate. The hole containing DMSO serves as a negative control and the hole containing the control compound with the highest FOI is used as a positive control. EC50 determination is performed by fitting the curve of the control activity percentage compared to the logarithm of the compound concentration using GraphPad Prism 6.0 software.
[0598] Example D. PD-L1 whole blood internalization analysis
[0599] To determine PD-L1 internalization in human whole blood, normal human blood (Biological SpecialtyCorp, Colmar.PA) was incubated in a 96-well "2ml Assay Block" (Corning, Corning NY) at 37°C for 18-20 hours in the presence or absence of a range of test compounds and 1ng / ml human interferon gamma (R&D Systems Inc. Minn.MN). The blood was then stained with PD-L1 (MIH1, eBioscience; or BD Biosciences San Jose, CA), CD14 (Life Technologies, Carlsbad, CA) for 30 minutes at room temperature in the dark. Whole blood / erythrocytes were lysed / fixed (lysis buffer, BD Biosciences) for 5 minutes in the dark at 37°C and then centrifuged at 1600RPM for 5 minutes. The cells were resuspended in staining buffer (BD Bioscience, San Jose, CA) and transferred to a 96-well round-bottom plate (Corning). Cells were gated as CD14+ (BD Biosciences) and PD-L1 expression was measured by mean fluorescence intensity (MFI) (BD LSRFortessa TM IC was calculated by fitting the curve of compound inhibition percentage versus the logarithm of compound concentration using GraphPad Prism 7.0 software. 50 Determination.
[0600] Example E. In vivo pharmacokinetics in rats, monkeys and dogs
[0601] For in vivo pharmacokinetic experiments, test compounds were administered intravenously or via oral gavage to male Sprague Dawley rats, male beagledogs, or male and female cynomolgus monkeys. For intravenous administration, test compounds were administered at 0.5 to 1 mg / kg using a formulation of acidified saline containing 10% dimethylacetamide (DMAC), with rats being injected intravenously and dogs and monkeys being infused intravenously for 5 min or 10 min, respectively. For oral administration, test compounds were administered at 1.0 to 3.0 mg / kg using a citrate buffer (pH 3.5) containing 0.5% methylcellulose containing 5% DMAC. Blood samples were collected for 24 hours at various time points before and after administration. All blood samples were collected using EDTA as an anticoagulant and centrifuged to obtain plasma samples. The plasma concentration of the test compound was determined by LC-MS. The concentration of the test compound was determined using The WinNonlin software program (version 7.0, Pharsight Corporation) calculated PK parameters by standard non-compartmental methods using the measured plasma concentrations.
[0602] Cassette dosing of test compounds was performed in rats and monkeys to obtain preliminary PK parameters.
[0603] Example F. Results
[0604] As exemplified in Examples 1-66, compounds of the present disclosure were evaluated in each of the HTRF PD-1 / PD-L1 binding assay (Example A), SHP assay (Example B), NFAT assay (Example C), and whole blood internalization assay (Example D). The cutoff values for the range of values observed in each of the assays are shown. The results obtained for the tested compounds are shown in Table 15.
[0605]
[0606] Table 15
[0607]
[0608]
[0609]
[0610] From the foregoing description, various modifications of the present invention, except those described herein, will be apparent to those skilled in the art. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application, including but not limited to all patents, patent applications, and publications, is incorporated herein by reference in its entirety.
[0611] Specifically, the present invention includes but is not limited to the following:
[0612] 1. A compound of formula I:
[0613]
[0614] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0615] R 1 is methyl, CN, F, Cl or Br;
[0616] R 2 is methyl, CN, F, Cl or Br; and
[0617] R 3 H, C 1-4 Alkyl, C 3-8Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl, C 6-10 Aryl-C 1-2 alkyl, 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C 1-2 alkyl, 4-membered to 6-membered heterocycloalkyl or 4-membered to 6-membered heterocycloalkyl-C 1-2 alkyl-, wherein the 5- to 6-membered heteroaryl, the 5- to 6-membered heteroaryl-C 1-2 alkyl, the 4-membered to 6-membered heterocycloalkyl and the 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl-groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 The C 1-4 Alkyl, the C 3-8 Cycloalkyl, the C 3-8 Cycloalkyl-C 1-2 Alkyl-, the C 6-10 Aryl, the C 6-10 Aryl-C 1-2 alkyl, the 5-membered to 6-membered heteroaryl, the 5-membered to 6-membered heteroaryl-C 1-2 alkyl, the 4-membered to 6-membered heterocycloalkyl and the 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl- groups are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of CONH2, SO2NH2, COOH, OH, CON(CH3)2, CH3, F, Cl, Br, CN, ethyl, and propyl.
[0618] 2. A compound of formula I:
[0619]
[0620] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0621] R 1 is methyl, CN, F, Cl or Br;
[0622] R 2 is methyl, CN, F, Cl or Br; and
[0623] R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl, C 6-10 Aryl-C 1-2 alkyl, 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C1-2 alkyl, 4-membered to 6-membered heterocycloalkyl or 4-membered to 6-membered heterocycloalkyl-C 1-2 alkyl-, wherein the 5- to 6-membered heteroaryl, the 5- to 6-membered heteroaryl-C 1-2 alkyl, the 4-membered to 6-membered heterocycloalkyl and the 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl-groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 The C 1-4 Alkyl, the C 3-8 Cycloalkyl, the C 3-8 Cycloalkyl-C 1-2 Alkyl-, the C 6-10 Aryl, the C 6-10 Aryl-C 1-2 alkyl, the 5-membered to 6-membered heteroaryl, the 5-membered to 6-membered heteroaryl-C 1-2 alkyl, the 4-membered to 6-membered heterocycloalkyl and the 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl- groups are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of CONH2, SO2NH2, COOH and OH.
[0624] 3. The compound according to item 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is methyl, F, Cl or Br.
[0625] 4. The compound according to item 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 It is methyl.
[0626] 5. The compound according to item 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is F, Cl or Br.
[0627] 6. The compound according to item 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 For Cl.
[0628] 7. A compound according to item 1 to 6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 It is methyl.
[0629] 8. A compound according to item 1 to 6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 For CN.
[0630] 9. A compound according to claim 1 to 6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 is F, Cl or Br.
[0631] 10. A compound according to item 1 to 6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 For Cl.
[0632] 11. The compound according to item 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 Cl and R 2 For Cl.
[0633] 12. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 Cl and R 2 It is methyl.
[0634] 13. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is methyl and R 2 For Cl.
[0635] 14. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 Cl and R 2 For CN.
[0636] 15. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is methyl and R 2 It is methyl.
[0637] 16. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or a 4- to 6-membered heterocycloalkyl group, wherein the 5- to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 The C 1-4 Alkyl, the C 3-8 Cycloalkyl, the C 3-8 Cycloalkyl-C 1-2 Alkyl-, the C 6-10 Aryl-C 1-2 alkyl, the 5-membered to 6-membered heteroaryl-C 1-2The alkyl group and the 4- to 6-membered heterocycloalkyl group are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of CONH2, SO2NH2, COOH, OH, CON(CH3)2, and CH3.
[0638] 17. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or a 4- to 6-membered heterocycloalkyl group, wherein the 5- to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 The C 1-4 Alkyl, the C 3-8 Cycloalkyl, the C 3-8 Cycloalkyl-C 1-2 Alkyl-, the C 6-10 Aryl-C 1-2 alkyl, the 5-membered to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of CONH2, SO2NH2, COOH and OH.
[0639] 18. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 For H.
[0640] 19. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 C 1-4 Alkyl, optionally substituted with 1 or 2 substituents independently selected from COOH, OH and CON(CH3)2.
[0641] 20. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 C 1-4 Alkyl, optionally substituted with 1 or 2 substituents independently selected from COOH and OH.
[0642] 21. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3It is methyl, ethyl, isopropyl, 1,3-dihydroxypropan-2-yl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 3-carboxypropyl, 2-carboxy-2-methylpropyl or 4-carboxybutyl.
[0643] 22. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 It is methyl, ethyl, isopropyl, 1,3-dihydroxypropan-2-yl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 3-carboxypropyl or 2-carboxy-2-methylpropyl.
[0644] 23. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 C 3-8 Cycloalkyl, optionally substituted with 1 or 2 substituents independently selected from COOH, OH and CH3.
[0645] 24. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 C 3-8 Cycloalkyl, optionally substituted with 1 or 2 substituents independently selected from COOH and OH.
[0646] 25. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 C 3-8 Cycloalkyl-C 1-2 Alkyl-, optionally substituted with 1 or 2 substituents independently selected from COOH and OH.
[0647] 26. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 C 6-10 Aryl-C 1-2 Alkyl, optionally substituted with 1 or 2 substituents independently selected from COOH and OH.
[0648] 27. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 It is cyclobutyl, 4-hydroxycyclohexyl, (1-carboxycyclopropyl)methyl, (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl, (4-carboxybicyclo[2.2.1]hept-1-yl)methyl, (4-carboxybicyclo[2.2.2]oct-1-yl)methyl, (3-carboxybicyclo[1.1.1]pent-1-yl)methyl, 4-carboxyphenethyl, (4-carboxycyclohexyl)ethyl or 4-carboxy-4-methylcyclohexyl.
[0649] 28. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 It is cyclobutyl, 4-hydroxycyclohexyl, (1-carboxycyclopropyl)methyl, (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl, (4-carboxybicyclo[2.2.1]hept-1-yl)methyl, (4-carboxybicyclo[2.2.2]oct-1-yl)methyl, (3-carboxybicyclo[1.1.1]pent-1-yl)methyl or 4-carboxyphenethyl.
[0650] 29. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is a 5- to 6-membered heteroaryl-C 1-2 Alkyl, optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2 and COOH.
[0651] 30. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is a 4- to 6-membered heterocycloalkyl group, optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2 and COOH.
[0652] 31. A compound according to any one of claims 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 It is (1H-pyrazol-3-yl)methyl, tetrahydro-2H-pyran-4-yl, 1-carbamoylpiperidin-4-yl, 1-sulfamoylpiperidin-4-yl or (3-carboxy-1H-pyrazol-5-yl)methyl.
[0653] 32. A compound according to claim 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is H, methyl, ethyl, isopropyl, 1,3-dihydroxypropan-2-yl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 3-carboxypropyl, 2-carboxy-2-methylpropyl, cyclobutyl, 4-hydroxycyclohexyl, (1-carboxycyclopropyl)methyl, (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl, (4-carboxybicyclo[2.2.1]hept-1-yl)methyl, (4-carboxy 1-yl)methyl, (3-carboxybicyclo[2.2.2]oct-1-yl)methyl, (3-carboxybicyclo[1.1.1]pent-1-yl)methyl, 4-carboxyphenethyl, (1H-pyrazol-3-yl)methyl, tetrahydro-2H-pyran-4-yl, 1-carbamoylpiperidin-4-yl, 1-sulfamoylpiperidin-4-yl, (3-carboxy-1H-pyrazol-5-yl)methyl, 4-carboxybutyl, (4-carboxycyclohexyl)ethyl or 4-carboxy-4-methylcyclohexyl.
[0654] 33. A compound according to claim 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is H, methyl, ethyl, isopropyl, 1,3-dihydroxypropan-2-yl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 3-carboxypropyl, 2-carboxy-2-methylpropyl, cyclobutyl, 4-hydroxycyclohexyl, (1-carboxycyclopropyl)methyl, (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl, (4-carboxybicyclo[2.2 .1]hept-1-yl)methyl, (4-carboxybicyclo[2.2.2]oct-1-yl)methyl, (3-carboxybicyclo[1.1.1]pentan-1-yl)methyl, 4-carboxyphenethyl, (1H-pyrazol-3-yl)methyl, tetrahydro-2H-pyran-4-yl, 1-carbamoylpiperidin-4-yl, 1-sulfamoylpiperidin-4-yl or (3-carboxy-1H-pyrazol-5-yl)methyl.
[0655] 34. A compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0656] R 1 is methyl, CN, F, Cl or Br;
[0657] R 2 is methyl, CN, F, Cl or Br; and
[0658] R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or a 4- to 6-membered heterocycloalkyl group, wherein the 5- to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 The C 1-4 Alkyl, the C 3-8 Cycloalkyl, the C 3-8 Cycloalkyl-C 1-2 Alkyl-, the C 6-10 Aryl-C 1-2 alkyl, the 5-membered to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of CONH2, SO2NH2, COOH, OH, CON(CH3)2, and CH3.
[0659] 35. A compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0660] R 1 is methyl, CN, F, Cl or Br;
[0661] R 2 is methyl, CN, F, Cl or Br; and
[0662] R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or a 4- to 6-membered heterocycloalkyl group, wherein the 5- to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 The C 1-4 Alkyl, the C 3-8 Cycloalkyl, the C 3-8 Cycloalkyl-C 1-2 Alkyl-, the C 6-10 Aryl-C 1-2 alkyl, the 5-membered to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of CONH2, SO2NH2, COOH and OH.
[0663] 36. A compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0664] R 1 Methyl or Cl;
[0665] R 2 is methyl, CN or Cl; and
[0666] R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or a 4- to 6-membered heterocycloalkyl group, wherein the 5- to 6-membered heteroaryl-C 1-2The alkyl group and the 4- to 6-membered heterocycloalkyl group each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 The C 1-4 Alkyl, the C 3-8 Cycloalkyl, the C 3-8 Cycloalkyl-C 1-2 Alkyl-, the C 6-10 Aryl-C 1-2 alkyl, the 5-membered to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of CONH2, SO2NH2, COOH, OH, CON(CH3)2, and CH3.
[0667] 37. A compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0668] R 1 Methyl or Cl;
[0669] R 2 is methyl, CN or Cl; and
[0670] R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl-C 1-2 Alkyl, 5- to 6-membered heteroaryl-C 1-2 alkyl or a 4- to 6-membered heterocycloalkyl group, wherein the 5- to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 The C 1-4 Alkyl, the C 3-8 Cycloalkyl, the C 3-8 Cycloalkyl-C 1-2 Alkyl-, the C 6-10 Aryl-C 1-2 alkyl, the 5-membered to 6-membered heteroaryl-C 1-2 The alkyl group and the 4- to 6-membered heterocycloalkyl group are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of CONH2, SO2NH2, COOH and OH.
[0671] 38. A compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0672] R 1Methyl or Cl;
[0673] R 2 is methyl, CN or Cl; and
[0674] R 3 is H, methyl, ethyl, isopropyl, 1,3-dihydroxypropan-2-yl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 3-carboxypropyl, 2-carboxy-2-methylpropyl, cyclobutyl, 4-hydroxycyclohexyl, (1-carboxycyclopropyl)methyl, (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl, (4-carboxybicyclo[2.2.1]hept-1-yl)methyl, (4-carboxy 1-yl)methyl, (3-carboxybicyclo[2.2.2]oct-1-yl)methyl, (3-carboxybicyclo[1.1.1]pent-1-yl)methyl, 4-carboxyphenethyl, (1H-pyrazol-3-yl)methyl, tetrahydro-2H-pyran-4-yl, 1-carbamoylpiperidin-4-yl, 1-sulfamoylpiperidin-4-yl, (3-carboxy-1H-pyrazol-5-yl)methyl, 4-carboxybutyl, (4-carboxycyclohexyl)ethyl or 4-carboxy-4-methylcyclohexyl.
[0675] 39. The compound of claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
[0676] R 1 Methyl or Cl;
[0677] R 2 is methyl, CN or Cl; and
[0678] R 3 is H, methyl, ethyl, isopropyl, 1,3-dihydroxypropan-2-yl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl, 3-hydroxypropyl, carboxymethyl, 3-carboxypropyl, 2-carboxy-2-methylpropyl, cyclobutyl, 4-hydroxycyclohexyl, (1-carboxycyclopropyl)methyl, (4-carboxybicyclo[2.2.1]hept-1-yl)ethyl, (4-carboxybicyclo[2.2 .1]hept-1-yl)methyl, (4-carboxybicyclo[2.2.2]oct-1-yl)methyl, (3-carboxybicyclo[1.1.1]pentan-1-yl)methyl, 4-carboxyphenethyl, (1H-pyrazol-3-yl)methyl, tetrahydro-2H-pyran-4-yl, 1-carbamoylpiperidin-4-yl, 1-sulfamoylpiperidin-4-yl or (3-carboxy-1H-pyrazol-5-yl)methyl.
[0679] 40. A compound as described in item 1, wherein the compound is selected from:
[0680] 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0681] 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0682] 4-(2-(2-((2,2'-dichloro-3'-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0683] 4-(2-(2-((2,2'-dichloro-3'-(5-ethyl-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0684] 4-(2-(2-((2,2'-dichloro-3'-(5-isopropyl-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0685] 4-(2-(2-((2,2'-dichloro-3'-(5-cyclobutyl-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0686] 4-(2-(2-((3'-(5-(1-carbamoylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0687] 4-(2-(2-((2,2'-dichloro-3'-(1-methyl-5-(1-sulfamoylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0688] 4-(2-(2-((3'-(5-((1H-pyrazol-3-yl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0689] 4-(2-(2-((2,2'-dichloro-3'-(5-(1,3-dihydroxypropan-2-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0690] (R)-4-(2-(2-((2,2'-dichloro-3'-(5-(2,3-dihydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0691] (S)-4-(2-(2-((2,2'-dichloro-3'-(5-(2,3-dihydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0692] (R)-4-(2-(2-((2,2'-dichloro-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0693] (S)-4-(2-(2-((2,2'-dichloro-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0694] 4-(2-(2-((2,2'-dichloro-3'-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0695] 4-(2-(2-((2,2'-dichloro-3'-(5-(3-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0696] 4,4'-(((((2,2'-dichloro-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid);
[0697] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0698] 4-(2-(2-((3'-(5-(carboxymethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0699] 4-(2-(2-((3'-(5-(3-carboxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0700] 4-(2-(2-((3'-(5-(2-carboxy-2-methylpropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0701] 4-(2-(2-((3'-(5-((1-carboxycyclopropyl)methyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0702] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.2]octane-1-carboxylic acid;
[0703] 3-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[1.1.1]pentane-1-carboxylic acid;
[0704] 4-(2-(2-((3'-(5-(4-carboxyphenethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0705] 5-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)-1H-pyrazole-3-carboxylic acid;
[0706] 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0707] 4-(2-(2-((2-chloro-2'-methyl-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0708] 4-(2-(2-((2-chloro-3'-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0709] 4-(2-(2-((3'-(5-(1-carbamoylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chloro-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0710] (R)-4-(2-(2-((2-chloro-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0711] (S)-4-(2-(2-((2-chloro-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0712] 4-(2-(2-((2-chloro-3'-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0713] 4,4'-(((((2-chloro-2'-methyl-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid);
[0714] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-chloro-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0715] 4-(2-(2-((3'-(5-(4-carboxyphenethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chloro-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0716] 4-(2-(2-((2'-chloro-2-methyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0717] 4-(2-(2-((2'-chloro-2-methyl-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0718] 4-(2-(2-((2'-chloro-3'-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0719] 4-(2-(2-((3'-(5-(1-carbamoylpiperidin-4-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-chloro-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0720] (R)-4-(2-(2-((2'-chloro-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0721] (S)-4-(2-(2-((2'-chloro-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0722] 4-(2-(2-((2'-chloro-3'-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0723] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-chloro-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0724] 4-(2-(2-((3'-(5-(4-carboxyphenethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-chloro-2-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0725] 4-(2-(2-((2-chloro-2'-cyano-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0726] 4-(2-(2-((2-chloro-2'-cyano-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0727] 4-(2-(2-((2-chloro-2'-cyano-3'-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0728] (R)-4-(2-(2-((2-chloro-2'-cyano-3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0729] 4-(2-(2-((2-chloro-2'-cyano-3'-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0730] 4,4'-(((((2-chloro-2'-cyano-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid);
[0731] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-chloro-2-cyano-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0732] 4-(2-(2-((2,2'-dimethyl-3'-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0733] 4,4'-(((((2,2'-dimethyl-[1,1'-biphenyl]-3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-diyl))bis(ethane-2,1-diyl))bis(bicyclo[2.2.1]heptane-1-carboxylic acid);
[0734] 4-((2-((3'-(5-(2-(4-carboxybicyclo[2.2.1]hept-1-yl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0735] 4-(2-(2-((2,2'-dimethyl-3'-(1-methyl-5-(tetrahydro-2H-pyran-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0736] (R)-4-(2-(2-((3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0737] (S)-4-(2-(2-((3'-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0738] 4-(2-(2-((3'-(5-(2-hydroxyethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dimethyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0739] 4-(2-(2-((2,2'-dichloro-3'-(5-(4-hydroxycyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; and
[0740] 4-(2-(2-((2-chloro-3'-(5-(4-hydroxycyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2'-methyl-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0741] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0742] 41. A compound as described in item 1, wherein the compound is selected from:
[0743] 4-(2-(2-((3'-(5-(2-(trans-4-carboxycyclohexyl)ethyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0744] 4-(2-(2-((3'-(5-(4-carboxybutyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0745] 4-(2-(2-((2,2'-dichloro-3'-(5-(5-(dimethylamino)-5-oxopentyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-carboxamido)-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0746] 4-(2-(2-((3'-(5-(cis-4-carboxy-4-methylcyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid; and
[0747] 4-(2-(2-((3'-(5-(trans-4-carboxy-4-methylcyclohexyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2'-dichloro-[1,1'-biphenyl]-3-yl)carbamoyl)-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)ethyl)bicyclo[2.2.1]heptane-1-carboxylic acid;
[0748] or a pharmaceutically acceptable salt or stereoisomer thereof.
[0749] 42. A pharmaceutical composition comprising a compound as described in items 1 to 41 or a pharmaceutically acceptable salt or stereoisomer thereof and a pharmaceutically acceptable excipient or carrier.
[0750] 43. A method for inhibiting PD-1 / PD-L1 interaction, the method comprising administering to a patient a compound as described in items 1 to 41 or a pharmaceutically acceptable salt or stereoisomer thereof.
[0751] 44. A method for treating a disease or condition associated with inhibiting PD-1 / PD-L1 interaction, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound as described in items 1 to 41 or a pharmaceutically acceptable salt or stereoisomer thereof.
[0752] 45. The method of item 44, wherein the disease or disorder is an infectious disease, inflammation, an autoimmune disease, cancer, or a neurodegenerative disorder.
[0753] 46. A method for enhancing, stimulating and / or increasing a patient's immune response, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound as described in items 1 to 41 or a pharmaceutically acceptable salt or stereoisomer thereof.
Claims
1. A compound of formula I: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is methyl, CN, F, Cl or Br; R 2 is methyl, CN, F, Cl or Br; and R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl, C 6-10 Aryl-C 1-2 alkyl, 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C 1-2 alkyl, 4-membered to 6-membered heterocycloalkyl or 4-membered to 6-membered heterocycloalkyl-C 1-2 alkyl-, wherein the 5- to 6-membered heteroaryl, the 5- to 6-membered heteroaryl-C 1-2 alkyl, the 4-membered to 6-membered heterocycloalkyl and the 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl-groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 The C 1-4 Alkyl, the C 3-8 Cycloalkyl, the C 3-8 Cycloalkyl-C 1-2 Alkyl-, the C 6-10 Aryl, the C 6-10 Aryl-C 1-2 alkyl, the 5-membered to 6-membered heteroaryl, the 5-membered to 6-membered heteroaryl-C 1-2 alkyl, the 4-membered to 6-membered heterocycloalkyl and the 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl- groups are each optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2, COOH, OH, CON(CH3)2, CH3, F, Cl, Br, CN, ethyl and propyl.
2. A compound of formula I: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is methyl, CN, F, Cl or Br; R 2 is methyl, CN, F, Cl or Br; and R 3 H, C 1-4 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl-C 1-2 Alkyl-, C 6-10 Aryl, C 6-10 Aryl-C 1-2 alkyl, 5-membered to 6-membered heteroaryl, 5-membered to 6-membered heteroaryl-C 1-2 alkyl, 4-membered to 6-membered heterocycloalkyl or 4-membered to 6-membered heterocycloalkyl-C 1-2 alkyl-, wherein the 5- to 6-membered heteroaryl, the 5- to 6-membered heteroaryl-C 1-2 alkyl, the 4-membered to 6-membered heterocycloalkyl and the 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl-groups each have one or two heteroatoms selected from O, N and S as ring members, and wherein R 3 The C 1-4 Alkyl, the C 3-8 Cycloalkyl, the C 3-8 Cycloalkyl-C 1-2 Alkyl-, the C 6-10 Aryl, the C 6-10 Aryl-C 1-2 alkyl, the 5-membered to 6-membered heteroaryl, the 5-membered to 6-membered heteroaryl-C 1-2 alkyl, the 4-membered to 6-membered heterocycloalkyl and the 4-membered to 6-membered heterocycloalkyl-C 1-2 The alkyl- groups are each optionally substituted with 1 or 2 substituents independently selected from the group consisting of CONH2, SO2NH2, COOH and OH.
3. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is methyl, F, Cl or Br.
4. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 It is methyl.
5. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is F, Cl or Br.
6. The compound according to claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 For Cl.
7. The compound according to claim 1 to 6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 It is methyl.
8. The compound according to claim 1 to 6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 For CN.
9. The compound according to claim 1 to 6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 is F, Cl or Br.
10. The compound according to claim 1 to 6, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2 For Cl.
